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Cardiometabolic diseases is a growing health issue worldwide. New knowledge about the 
pathophysiological processes have been gained and several research discoveries have 
contributed to better management of the diseases. Even so, the prognosis, diagnosis, and 
treatment of cardiometabolic diseases needs to be further improved. For this, the discovery 
and implementation of additional biomarkers is extremely relevant. New advancing 
technologies have increased the opportunities to perform discovery studies and to identify 
new potential biomarkers. However, for several reasons, only few biomarkers survive the 
long journey from discovery into clinical implementation and there is a need to make this 
process more efficient.  
The objective of the thesis was to evaluate new potential biomarkers to improve the diagnosis 
and management of cardiometabolic diseases. An additional aim was to establish an efficient 
process for rapid transfer of new potential biomarkers, identified in discovery studies into 
evaluation in the routine care setting. Four studies in different patient cohorts, characterized 
by separate designs, and reflecting diverse phases in the implementation of biomarkers for 
cardiometabolic diseases are presented.  
Lipoprotein (a) [Lp(a)] is a modified low-density lipoprotein (LDL) particle and its 
concentration in plasma is mainly genetically determined. High levels of Lp(a) is associated 
with an increased risk for cardiovascular diseases (CVD). Despite the fact that it is not yet 
clear whether reduction of plasma Lp(a) levels translate into a reduced CVD risk, more 
knowledge about its role as a risk factor in different cohorts and diagnoses is needed to better 
understand how patients with high Lp(a) levels should be managed.  
In Paper I we investigated the distribution of plasma Lp(a) levels and its association with 
CVD in a large cohort of patients who had their plasma levels of Lp(a) determined in routine 
care. Laboratory data from 23 398 patients was linked to data retrieved from National Board 
of Health and Welfare registers and National Quality registers. Lp(a) levels had a skewed 
distribution, increased with age, and was higher in females. Patients with Lp(a) levels in the 
4th quartile had a 1.36-fold (95% Confidence Interval (CI) 1.14-1.61, p=0.001) increased risk 
for ischemic heart disease compared to patients belonging to the 1st quartile. The risk was 
independent of age, previous CVD, diabetes, and LDL-cholesterol levels. Hence, Lp(a) is an 
important risk factor for ischemic heart disease also in patients referred from hospitals, out-
patient clinics, and general practitioners in the Region Stockholm.  
Very little is known about the role of Lp(a) as a risk factor for CVD in patients with type 1 
diabetes. Therefore, in Paper II we investigated the association of Lp(a) with cardiovascular 
complications and metabolic control in 1860 subjects with type 1 diabetes. Lp(a) levels had a 
skewed distribution, increased with age, and was not influenced by sex. Patients with poor 
metabolic control (HbA1c >52 mmol/mol) had higher Lp(a) levels compared to patients with 
good metabolic control. Patients with high Lp(a) levels (>120 nmol/L) had a 1.51-fold (95 % 
CI 1.01-2.28, p=0.048) increased risk for any macrovascular diseases, a 1.68-fold (95% CI 
1.12-2.50, p=0.01) increased risk for albuminuria, and a 2.03-fold (95 % CI 1.02-4.01, 
p=0.043) increased risk for calcified aortic valve disease compared to patients with very low 
levels (<10 nmol/L). In summary, Lp(a) is a relevant risk factor also in patients with type 1 
diabetes.  
In Paper III we aimed to establish an efficient process for transfer of newly discovered 
potential biomarkers into evaluation in the routine care setting. The prototype was based on 
the evaluation of chemokine ligand 16 (CCL-16), previously identified as interesting 
biomarker for acute coronary syndrome (ACS) in a discovery project called Vinncardio, 
initiated by the Science for Life laboratory, Royal Institute of Technology (KTH), Stockholm, 
Sweden. Patients eligible for inclusion were identified when their plasma was analyzed for 
high sensitive Troponin T at the Karolinska University Laboratory, Stockholm, Sweden. The 
plasma samples were temporarily stored and meanwhile the patients received a letter of 
invitation to participate in the study. A positive response was retrieved from ~40 % and 1631 
patients were included. No significant differences in CCL-16 were observed between patients 
with ACS and other diagnosis and CCL-16 do not appear to be a valid biomarker for ACS. 
Despite this negative result, we manage to establish a process for early evaluation of new 
potential biomarkers in routine care settings and to rapidly create a biobank and include 
patients referred to the hospital with an acute medical condition.  
Clinical randomized trials have shown that addition of ezetimibe to simvastatin treatment 
further improve the reduction of CVD events, especially in patients with type 2 diabetes 
where elevation of remnant-cholesterol is characteristic. Remnant-cholesterol is a new and 
interesting biomarker and mendelian randomization studies have identified it as an 
independent risk factor for CVD, also promoting and sustaining low grade inflammation. In 
Paper IV we aimed to in detail study how the lipoprotein metabolism is affected by 
simvastatin and ezetimibe treatment, alone or in combination, to gain further understanding 
of the molecular effects of these two widely used lipid lowering drugs. Forty patients eligible 
for cholecystectomy were randomized to four-week treatment before surgery to placebo, 
simvastatin (80 mg daily), ezetimibe (10 mg daily), or to combination of both. The 
combination of simvastatin and ezetimibe resulted in further reduction of cholesterol and 
cholesteryl esters in remnant- and LDL-particles, as well as reduction of apolipoprotein B 
(apoB) containing particles, and reduced apoB-containing lipoprotein affinity for arterial 
proteoglycans compared to simvastatin. These additional positive effects on atherogenic 
lipoproteins and especially remnant-particles can possibly explain the further reduction of 
CVD events previously observed, and the combination of ezetimibe and simvastatin seems to 
be the optimal treatment in conditions with elevated remnant-cholesterol.  
In conclusion, these four studies have provided further knowledge about the different 
biomarkers investigated. Also, they can contribute to an improved management of patients 
with cardiometabolic diseases and indicate the way to a rapid recruitment of patients in 
clinical studies. Hence, this thesis adds to a deeper understanding of the complexity in the 
process to validate and implement new biomarkers.   
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Why are only approximately 100 different biomarkers currently used in the clinic, though 
>150 000 potential new biomarkers have been suggested from discover studies (1)? Is there no 
need for more biomarkers? Are those identified biomarkers false? Is the process to establish 
new biomarkers too challenging or is their clinical implementation too complex?  
Unfortunately, this thesis will not answer all these questions, but it will present further 
understanding of the challenges that the search for biomarkers presents, with the hope to 
contribute with novel approaches for the evaluation of potential biomarkers in clinical settings.   
1.1.1 Definition and characteristics of biomarkers 
Biomarkers should reflect a stage in the pathophysiological process of diseases. They have a 
broad area of use, including screening of patients, prognosis, diagnosis, and monitoring of 
diseases, as well as to be surrogate end point in clinical trials. Some biomarkers are also risk 
factors since they are not only involved in the pathophysiological process but are also causal for 
the disease. However, the difference between a biomarker and a risk factor is subtle (2, 3). 
The optimum features of biomarkers depend on their intended use, but some features are 
generally desirable. They should be specific and able to distinguish definite pathologic 
conditions from physiologic states or from other diseases, be measurable in accessible 
biological sources (e.g. blood, urine), be quantifiable with accurate assays, and defined 
reference levels should also be available (2). A relevant biomarker should add value to existing 
biomarkers, be generalizable to different populations, easy to interpret for the clinicians, and 
have proven cost effectiveness (3-5).  
1.1.2 Biomarker research  
Before starting projects aiming to discover new biomarkers, it is important to consider whether 
there are real needs for the healthcare that are not met by the already available biomarkers. 
Otherwise the outcomes of those projects cannot be implemented in clinical settings.  
The strategy leading to biomarker implementation in the routine care can be divided into the 
following phases: discovery, qualification, verification, assay development, and evaluation. The 
discovery phase should be characterized by an unbiased approach and identify a definite 
number of possible new biomarkers that is not too excessive, otherwise this phase fails to 
identify relevant candidates. This indeed is a potential threat in discovery studies were 
genomics, proteomics, metabolomics, and pharmacogenomics are used. Careful selection of 
samples for screening in the discovery phase is also very important to prevent bias and to favor 
the identification of truly relevant candidates. Selection of the top candidates to be further 
 
2 
qualified should be based on literature reviewing, biological knowledge and performance in the 
discovery phase (2, 3, 6).  
The qualification phase of top candidate biomarkers aims to assess the translatability of the 
discoveries. For example, if an animal model has been used to identify the candidate biomarker, 
it is mandatory to prove that this is detectible in human samples and differently expressed in 
healthy and pathological conditions. Similar needs are also present when human material stored 
in biobanks is used in the discovery phase. In the next phase, verification of the candidate 
biomarkers should be performed in a larger number of samples in order to test the sensitivity 
and specificity by using cases and controls (6).  
Suitable technologies with acceptable analytical performance, including accuracy (bias), 
precision (repeatability and reproducibility), and measurement range (linearity, lower level of 
detection and lower level of quantification) should be used to develop an assay for measurement 
of the biomarkers before evaluation in clinical care settings. In addition, the optimal 
preanalytical conditions for the biomarkers should be determined (6-11).   
The strategy for evaluation in clinical care settings depends on the conditions and the intended 
use of the biomarkers. However, some general important parts are the determination of 
reference levels in healthy individuals and the levels of the biomarkers in patients with different 
diseases, in order to understand the consequences of pathological values (3, 6). It is also 
important to test the performance of the biomarkers in term of possible prediction of the 
diseases and outcomes in prospective trials (3, 11). It is thus obvious that evaluation and 
implementation of biomarkers for routine use in healthcare can take many years, require great 
efforts, and that many candidates fail during the process. Hence, it is very important to have a 
common strategy designed in collaboration between the research laboratory, the routine 
laboratory, and the clinicians from the start (12, 13).  
1.2 CARDIOMETABOLIC DISEASE 
The definition of cardiometabolic diseases is ambiguous. In this text it is referred to a group of 
diseases in which metabolic disorders (e.g. metabolic syndrome, diabetes, dyslipidemia) 
accelerate and cause the development of cardiovascular diseases (CVD).   
1.3 CARDIOVASCULAR DISEASES (CVD)  
CVD comprise a variety of conditions in the heart and blood vessels including coronary heart 
disease, cerebrovascular disease, peripheral vascular disease, heart failure, rheumatic heart 
disease, cardiomyopathies, and congenital heart disease. Atherosclerosis is an important 
component in the development of CVD and dyslipidemia, inflammation and the immune 
response are all causal factors in atherogenesis (14).   
CVD is the leading cause of morbidity and mortality worldwide, and the World Health 
Organization mention CVD as a threat to global health in 2019. In the European Union, 
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approximately 1.8 million die from CVD every year, accounting for more than 35 % of all 
deaths and is considerable higher than cancer that is the second most common cause of death 
(15). In Sweden, CVD accounts for approximately 33 % of all deaths (National Board of Health 
and Welfare statistics for causes of death 2018) and over 2 million people have a CVD (16).  
Overall, the prevalence of CVD has declined over the last 20 years and the outcome of CVD 
has improved. However, there is an inequality in CVD burden and deaths across the countries, 
where low- and middle-income countries are more affected than the high-income countries (15-
18). Better primary and secondary prevention, including treatment with statins and 
antihypertensive drugs, as well as lifestyle interventions and decreased smoking rates, have all 
contributed to the reduction of CVD and its sequelae. Unfortunately, other pathologic 
conditions, such as obesity and type 2 diabetes, are increasing and this explain why CVD is now 
a major global health issue (3, 15, 18). Early identification of individuals at high risk for CVD is 
essential to further improve the prevention and treatment of the diseases and biomarkers can 
contribute to this process.  
1.3.1 Estimating the CVD risk 
CVD risk factors are numerous. Some risk factors are modifiable (e.g. smoking, dyslipidemia, 
diabetes, hypertension, and unhealthy lifestyles) while others are not (e.g. sex, age, and 
genome). Additional circumstances, such as presence of other comorbidities, epigenetics, and 
psychosocial and environmental factors, may also influence the CVD risk further (4, 18, 19). 
Several tools have been developed to assist in CVD risk estimation. The different tools adopted 
in different countries show similar performance when used in the correct populations. A 
commonly used risk assessment tool for European populations is the Systematic Coronary Risk 
Estimation (SCORE) that based on age, sex, smoking status, blood pressure, and total 
cholesterol estimate an individual’s 10-year risk for CVD-related mortality. Other risk 
assessment tools to estimate the 10-year risk for CVD events are the Framingham Risk Score 
based on an American population and the QRISK that are developed in the United Kingdom 
(18).  
CVD risk estimation using a risk estimation system such as the SCORE is recommended for 
asymptomatic adults >40 years according to guidelines presented by the European 
Atherosclerosis Society (EAS) and European Society of Cardiology (ESC). The CVD risk is 
categorized as very-high (calculated SCORE ≥10 % for 10-year risk of fatal CVD), high 
(calculated SCORE ≥5 % of 10-year risk for fatal CVD), moderate (calculated SCORE ≥1 % 
for 10-year risk of fatal CVD), and low (calculated SCORE ≤1 % for 10-year risk of fatal 
CVD). Some individuals are classified to be at very-high or high CVD risk without the SCORE 
calculation, i.e. patients with established CVD, significant plaques visible on computer 
tomography scan or ultrasound, diabetes with organ damage or duration >20 years, chronic 
kidney disease (CKD) with estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2 or 
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patients with familial hypercholesterolemia. Young patients with shorter duration of diabetes 
are classified to be at moderate risk. Other contributing factors such as remnant-cholesterol, 
apolipoprotein B (apoB), triglycerides (TG), high density lipoprotein (HDL) cholesterol, 
Lipoprotein (a) [Lp(a)], C-reactive protein (CRP), and calcium score modifies the risk and can 
contribute to reclassification of the patient into another risk category (19).  
It is important to remember that the risk assessment is based on major risk factors from general 
population studies. Assessment of the individual’s CVD risk, considering additional risk 
modifying factors is challenging but crucial. In this context, biomarkers can help to improve the 
individual risk stratification and contribute to a more personalized medical care (20).  
1.3.2 Biomarkers for CVD  
Several different biomarkers for CVD are currently in use and many more have been suggested, 
including circulating biomarkers (e.g. troponins, natriuretic peptides, CRP, lipoproteins, 
apolipoproteins, copeptin, galectin-3, soluble suppression of tumorigenicity-2, growth derived 
factor 15 etc.), imaging biomarkers (e.g. calcium score, carotid intermedia thickness, and 
echocardiography), and anthropology measurement biomarkers (e.g. blood pressure, oxygen 
saturation, body mass index, and heart rate) (21). They can be categorized in several ways and 
usually according to the pathophysiological processes that the biomarkers are involved in. For 
example, biomarkers are categorized in relation to their role in myocardial injury, myocardial 
stress, inflammation, coagulation or metabolic disorders (e.g. dyslipidemia or glucose 
intolerance) (3, 18, 22).  
The search for new CVD biomarkers to further improve the individual risk assessment, 
prevention, diagnosis, prognosis and treatment of the diseases has been extensive, and a deep 
understanding of the pathophysiological mechanisms of the diseases is a prerequisite in this 
search (3, 4). The advanced techniques used in the biomarker discovery have in addition to 
identifying many candidate biomarkers, contributed to further understanding of the diseases. 
Genome wide association studies have generated new insights from genetic biomarkers and 
single nucleotide polymorphisms, and the mendelian randomization approach have revealed 
causal relationships of several biomarkers and CVD (2, 20, 21, 23, 24).  
1.4 LIPOPROTEINS AND CVD RISK  
1.4.1 Brief overview of lipoproteins 
In the circulation, fat molecules are transported in lipoproteins consisting of TG, free-
cholesterol, cholesteryl esters (CE), phospholipids, and proteins. The most TG rich lipoproteins 
in the circulation are chylomicrons (CM) and very low-density lipoproteins (VLDL). CM are 
large TG-rich particles, only synthesized in the intestine and the major structural protein is 
apolipoprotein B48. In the circulation exchange of apolipoproteins, preferably with HDL-
particles occurs and apolipoprotein C and apolipoprotein E are added to the CM. The enzyme 
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lipoprotein lipase (LPL) is present at the endothelial capillary cells and mostly expressed in 
adipose tissue, skeletal-, and cardiac muscle. Non esterified fatty acids (NEFA) released from 
the LPL-mediated hydrolysis of TG in CM are immediately absorbed by the tissues. The NEFA 
not absorbed are directed, bound to albumin, to the liver (so called spillover of NEFA). The 
muscle tissues are very effective in the uptake of NEFA, that are oxidized to produce energy. 
The uptake is less effective in white adipose tissue were NEFA are re-esterified to TG for 
storage. LPL and hydrolysis of TG are under strict hormonal regulation especially from insulin 
and catecholamines. Factors like apolipoprotein CIII, apolipoprotein E, and angiopoietin-like 
proteins also modulate LPL activity. After LPL mediated hydrolysis of TG, the remaining CM-
remnants are rapidly taken up by the liver (25-30).  
VLDL are synthesized by the liver and are smaller compared to CM. VLDL contains relatively 
less TG and more cholesterol, have a longer half-life in plasma (1-2 hours), and apolipoprotein 
B100 is the structural protein instead of apolipoprotein B48. After hydrolysis of TG by LPL in 
the circulation, VLDL became intermediate dense lipoproteins (IDL), also called VLDL-
remnant. The IDL are in turn further processed, also by the action of hepatic lipase into low-
density lipoprotein (LDL). LDL have a 2-3 days half-life, are the most abundant lipoproteins 
and transports most of the cholesterol in the circulation (27-30).  
The liver has a key role in the cholesterol homeostasis. It is the main organ for de novo 
synthesis, but it should be remembered that most cells in the body can synthesize cholesterol. 
The rate-limiting enzyme in cholesterol synthesis is 3-hydroxyl-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase. The liver can also acquire cholesterol from the circulation. The uptake 
of LDL is mediated by LDL-receptors that are mostly expressed in the liver but can be present 
on cell-surfaces in all cells. The dietary cholesterol absorbed in the small intestine is transported 
in CM from the gut into the circulation and finally to the liver as CM-remnants. HDL particles 
can carry cholesterol back to the liver by docking to the scavenger receptor type B class I (SR-
BI). The liver can excrete cholesterol into the circulation in VLDL or into the bile directly or 
after conversion into bile acids. A considerable amount of the bile acids and cholesterol secreted 
into bile are reabsorbed in the small intestine and returned to the liver in the enterohepatic 
circulation (27-30).  
 
HDL are important in the reverse cholesterol transport i.e. the transport of cholesterol from 
peripheral tissues back to the liver. HDL are synthesized from the intestine and the liver as 
nascent-HDL, consisting mainly of phospholipids, apolipoproteins and unesterified cholesterol. 
The characteristic apolipoprotein of HDL is apolipoprotein A1 (apoA1), a cofactor for lecithin 
cholesterol acetyltransferase (LCAT). Once in the circulation, HDL take up cholesterol that is 
esterified into CE by LCAT. The nascent HDL-particle gradually increases in CE content and 
turns into the mature HDL particle that exists in two subclasses with different density, HDL2 
and HDL3 (31, 32). The CE in HDL can be returned to the liver in different ways. The SR-B1 
removes CE from HDL in the liver while HDL remains in the circulation. In addition, CE can 
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be removed from HDL in exchange for TG from VLDL. This process is mediated by 
cholesteryl ester transfer protein (CETP), an enzyme that also exchange CE for TG between 
LDL and VLDL (28, 33, 34).  
1.4.2 Assessment of atherogenic lipoproteins for CVD risk estimation 
The evidences for LDL-cholesterol as causal factor for CVD are extensive as well as the 
beneficial effects of LDL-lowering therapies for both primary and secondary CVD prevention 
(35). However, all apoB containing lipoproteins up to ~70 nm in size, i.e. CM-remnants, VLDL, 
IDL, LDL, and Lp(a) can enter the endothelium and contribute to the development of 
atherosclerosis (36, 37).  
LDL is the most abundant of the apoB-containing particles in plasma and the major contributor 
of cholesterol depositions in the arterial wall (38). In conditions with elevated TG-rich particles 
or high Lp(a) levels, the contribution of other apoB-containing lipoproteins in the 
atherosclerotic process is more significant. This can add to the residual CVD risk seen in some 
patients even after reaching desirable LDL-cholesterol levels and assessment of biomarkers 
beyond LDL-cholesterol can in these cases improve estimation of an individual’s CVD risk (36, 
37, 39-41).  
A “standard” lipid profile includes measurement of total-cholesterol, HDL-cholesterol and TG. 
The LDL-cholesterol can either be calculated by the Friedewald’s formula (LDL-cholesterol = 
total-cholesterol – (0.45 x TG) – HDL-cholesterol) or directly measured. The reference method 
for LDL-cholesterol measurement is beta-quantification where the lipoprotein particles are 
partially separated by ultra-centrifugation. After removal of CM and VLDL the apoB-
containing particles (mainly LDL-cholesterol) in the bottom fraction are precipitated using 
heparin-manganese, the remaining HDL-cholesterol in the solution is quantified and LDL-
cholesterol can be calculated by subtraction of HDL-cholesterol from total cholesterol in the 
bottom fraction (42-44). This is a very time-consuming procedure and therefore Friedewald’s 
formula has been used to estimate LDL-cholesterol due to its simplicity, good precision, and 
cost effectiveness. Hence, most clinical studies have been or are based on calculated LDL-
cholesterol. Calculation of LDL-cholesterol assumes a constant ratio between VLDL-TG and 
cholesterol, no presence of CM or remnant-particles, and requires a fasting state. The estimation 
is imprecise in hypertriglyceridemia and should not be used if TG levels are > 4.5 mmol/L. 
Several homogenous assays with good reproducibility and specificity for direct measurement of 
LDL-cholesterol is commercially available today. Due to the great heterogenicity of LDL-
particles direct measurement is challenging, and diverse assays can distinguish in their ability to 
detect the different subfractions of LDL. Hence, the results can vary depending on the assay and 
especially in conditions with elevated TG levels (45, 46). Direct measurement of LDL-
cholesterol usually reports 10-20 % lower values compared to calculated LDL-cholesterol levels 
depending on the assay and TG levels (47-50). Both calculated and directly measured LDL-
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cholesterol includes the cholesterol content of Lp(a) (approximately 30 % of its mass) and can 
therefore be overestimated in patients with high Lp(a) levels (45, 46).  
LDL-cholesterol levels are especially important for CVD risk assessment and is the primary 
treatment target. In the ESC/EAS 2019 guidelines, a LDL-cholesterol reduction ≥50 % and 
levels less than 1.4 mmol/L in patients at very-high risk or levels less than 1.8 mmol/L in 
patients at high risk is recommended. Even lower LDL-target levels of 1.0 mmol/L are desirable 
in very-high risk patients with recurrent events (19). Intensive statin treatment and adding of 
other lipid lowering therapies is often required to reach these levels and in this era of very low 
LDL-cholesterol target levels, laboratory assays with improved precision at low levels are 
desirable.  
Elevated TG levels (41) and elevation of remnant-cholesterol (51) have both been demonstrated 
to be associated with increased CVD risk. The risk observed in hypertriglyceridemia seems to 
be due to elevated cholesterol content of atherogenic TG-rich particles rather than the TG per se 
(41). The cholesterol content of all atherogenic lipoproteins, i.e. the non-HDL cholesterol can 
be estimated by subtraction of HDL from total cholesterol and is preferable in risk estimation 
especially in conditions with hypertriglyceridemia and elevation of remnant-particles (i.e. 
diabetes, metabolic syndrome, and CKD) (46, 52). Reduction of non-HDL cholesterol reduce 
the CVD risk (53) and is recommended as a secondary treatment target in combined 
hyperlipidemia and conditions with elevated remnant-particles (19). Remnant-cholesterol is the 
cholesterol in non-HDL and non-LDL particles, i.e. the free cholesterol and CE carried in CM-
remnants, VLDL and IDL. It can be estimated both in the fasting and non-fasting state by 
subtraction of LDL- and HDL-cholesterol from total cholesterol. Remnant-cholesterol is a 
causal risk factor for ischemic heart disease (IHD) and in contrast to LDL-cholesterol also 
associated with low-grade inflammation and contribute to the residual CVD risk observed after 
LDL-cholesterol reduction (40, 51, 52, 54-57). In addition, remnant-cholesterol was recently 
shown to be associated with increased risk of ischemic stroke (58).  
All atherogenic lipoproteins derived from either VLDL or CM carries one apoB particle each, 
hence, the apoB level corresponds to their particle count in plasma. The use of apoB for CVD 
risk estimation has been investigated in several prospective population cohort studies (59-61) 
and meta-analysis (62-64). It seems to be at least equal to, but some suggests superior to LDL-
cholesterol in CVD risk assessment. The advantage is especially in dyslipidemias including 
increased TG-rich lipoproteins or when there is a discrepancy between LDL-cholesterol and 
apoB levels (62). In addition, reduction of apoB with statins or other common used LDL-
receptor dependent lipid lowering therapies can reduce the CVD risk (65). Therefore, 
measurements of apoB is recommended as an alternative CVD risk marker in combined 
hyperlipidemias or in patients with metabolic syndrome, diabetes or CKD, and can also be 
considered as a secondary treatment target. It may be preferred over non-HDL cholesterol since 
it is superior for estimation of atherogenic particle count in the circulation and in conditions 
with elevated small dense LDL-particles, this can be of special interest (19, 39). Other 
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advantages of apoB is the existing immunoassays with good analytical quality, that the 
measurement is independent of TG levels, and fasting is not required. Hence the analytical 
errors, especially when hypertriglyceridemia is present are less significant compared to LDL-
cholesterol (39, 52).  
1.4.3 Lipid lowering treatment with statins and ezetimibe  
Statins are the cornerstones in the treatment of dyslipidemia today. Lovastatin was the first 
statin approved by the U.S. Food and Drug Administration in 1989 for human use to lower 
cholesterol levels. It is a natural occurring compound in food, for example red yeast rice. Since 
then, substantial evidence of the positive effect of statins for lipid lowering, primary and 
secondary prevention of CVD exists (66). A statins is the first drug of choice for the 
management of hypercholesterolemia and dyslipidemias with few side effects (19, 67). The 
most frequently appearing side effect is statin associated muscle symptoms that can limit its use. 
To terminate treatment, lower the dose, or change to another statin can reduce this side effect 
(67, 68). 
Statins inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, and 
hence the cholesterol synthesis in the liver. Reduction of cholesterol synthesis results in 
increased expression of the LDL-receptor, increased uptake of LDL and other apoB-containing 
particles and a reduction of these atherogenic lipoproteins in the circulation (69). There is a dose 
dependent cholesterol reduction that varies between different types of statins. Rosuvastatin is 
the most potent statin and can lower the LDL-cholesterol levels up to approximately 60 % (66, 
70).  
Cholesterol from the diet is absorbed in the proximal jejunum in the small intestine where 
Niemann-Pick C1-like 1 (NPC1L1) is an important mediator. Ezetimibe is an inhibitor of 
NPC1L1 and reduces the intestinal absorption of cholesterol (71, 72). Thereby, ezetimibe can 
lower the LDL-cholesterol levels by approximately 15-20 %, and when added to statin 
treatment the additional reduction is 15-20 % (73, 74). The Study of Heart and Renal Protection 
(SHARP), a randomized double blind trial in approximately 9000 subjects with CKD, showed 
that the combination of simvastatin 20 mg daily and ezetimibe 10 mg daily safely reduced 
major atherosclerotic events by 17 % compared to placebo (75). The Vytorin Efficacy 
International Trial (IMPROVE-IT) showed an additional LDL-cholesterol lowering effect and 
improved CVD outcome by combined treatment with simvastatin 40 mg daily and ezetimibe 10 
mg daily compared to only simvastatin in 18 000 patients with previous acute coronary 
syndrome (ACS) (76, 77). The effect was most pronounced in patients with type 2 diabetes, 
where the dyslipidemia is characterized by elevated TG-rich lipoproteins (i.e. remnant-
particles), increased small dense LDL-particles, and low HDL-cholesterol levels (78, 79). It has 
also been shown that when ezetimibe is added to ongoing simvastatin treatment the remnant-
cholesterol is reduced further than just doubling the statin dose (80) 
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1.5 LIPOPROTEIN (A) [LP(A)] 
1.5.1 Metabolism of Lp(a) 
Lp(a) is a LDL-cholesterol particle with an apolipoprotein(a) [apo(a)] covalently bound by 
disulfide bridges to apolipoprotein B100 (81). The physiological function, metabolism, and 
catabolism of Lp(a) has not yet been described in detail and is an ongoing research area of 
interest (81, 82).  
Apo(a) is synthesized in the liver and binds to the LDL-particles. Exact where the binding takes 
place is not known, but the hepatocyte, space of Disses or the plasma compartment are possible 
locations (83). The major catabolic pathway for Lp(a) is believed to be through the liver and to 
a smaller extent through the kidneys (81). Alterations of plasma Lp(a) levels have been 
observed in patients with renal disease, supporting a role of the kidney in the Lp(a) metabolism 
(84, 85). The receptors involved in the catabolism remains obscure and the role of the LDL-
receptor is debated. Some studies have shown that Lp(a) binds to the LDL-receptor and that the 
interaction is important in the Lp(a) clearance but other studies have demonstrated the opposite 
(86-89). Additional receptors suggested to be involved in the catabolism of Lp(a) are the LDL-
receptor related protein, asialoglycoprotein receptors, macrophage scavenger receptors, and 
megalin gp330 receptors (90). Since treatment with proprotein convertase subtilisin/kexin type 
9 (PCSK9) inhibitors decrease plasma levels of Lp(a), a function of PCSK9 in the Lp(a) 
metabolism is plausible. A major role of PCSK9 in the secretion of Lp(a) from the hepatocytes 
has been suggested (91), while other studies demonstrate a role of PCSK9 in the Lp(a) 
catabolism (88, 92), and some suggests that the Lp(a) reduction from treatment with PCSK9-
inhibitor are mediated through other mechanisms than by PCSK9 (93).  
1.5.2 Genetics and phenotypes  
Plasma Lp(a) levels are mainly genetically determined and affected by ethnicity. Age, sex or 
lifestyle factors seems to be of minor importance. Apo(a) is coded from the LPA-gene on 
chromosome 6q2.6-q2.7. The LPA-gene share similarities with the plasminogen gene, 
consisting of two K-domains (IV and V) and of a protease domain, which is catalytically 
inactive (82, 90). The K IV-domain occurs in 10 different types, were the type 2 (KIV-2) have a 
large copy number variation and exist in multiple copies, from 1 to > 40. Every KIV-2 copy is 
5.5 kbp, consists of two exons separated by a long 4 kbp intron and, a short intron with 1.2 kbp 
separate each KIV-2 copy. The exon 1 is identical in all copies while exon 2 exists in three 
different types that are differentiated by synonymous mutations (82). Depending on the KIV-2 
copy number, the molecular weight of apo(a) varies between 200-800 kDa (94). A majority of 
the population (70-90 %) are heterozygous for the LPA alleles and have two different Lp(a) 
particles in the circulation (82, 95).  
Plasma Lp(a) levels are skewedly distributed in the population, ranges within three orders of 
magnitude, and are inversely correlated to the copy number of KIV-2. The correlation is not 
linear, and the strength varies between different populations. The strongest association between 
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KIV-2 copy numbers and Lp(a) levels has been demonstrated in Asian and European 
populations and are weaker in African populations (82). 
1.5.3 Role of Lp(a) in pathophysiological mechanisms 
Elevated plasma levels of Lp(a) are associated with increased risk for CVD, i.e. IHD, stroke, 
and calcified aortic valve disease (CAVD) (81, 96-100). Association with peripheral artery 
disease (PAD) and venous thromboembolism (VTE) has also been demonstrated (101, 102).  
The mechanism of Lp(a) in the pathogenesis of CVD is not fully understood, but is probably 
due to both atherogenic and prothrombotic properties of the particle (81). Lp(a) possess 
different pro-atherogenic characteristics, including interactions with endothelial cells, 
accumulation in the arterial wall, initiation of an pro-inflammatory response, and its carrying of 
a large amount of oxidized phospholipids (83, 90). The structurally similarity of apo(a) to 
plasminogen is important and Lp(a) is suggested to interfere with the plasminogen activity. 
Lp(a) can bind to similar structures as plasminogen but lacks fibrinolytic activity, resulting in an 
anti-fibrinolytic action (82, 90, 103). Other mechanisms for prothrombotic activity, including 
interference with tissue plasminogen activator, tissue factor pathway inhibitor, altered fibrin clot 
properties, and increased expression of plasminogen activator inhibitor-1 and tissue factor has 
also been suggested (90, 103). 
1.5.4 Laboratory assessment of Lp(a) 
The laboratory assessment of Lp(a) is challenging because of the great size heterogeneity of 
apo(a). The covalent binding between apo(a) and apoB, and the homology between apo(a) and 
plasminogen also contributes to the difficulty to develop specific antibodies against apo(a). Due 
to absence of a common reference material and harmonization of different Lp(a) assays, the 
consistency between laboratories has been poor. Since the reactivity of antibodies directed to 
the repeated segment in KIV-2 vary with the copy number, a calibrator cannot be representative 
for all apo(a) sizes and the assay will either overestimate or underestimate the Lp(a) 
concentration depending on whether the samples contains a larger or a smaller apo(a) size than 
the calibrator. Lp(a) has historically been measured by immunoassays that report total mass 
concentration of Lp(a). Today several different assays that report Lp(a) in mass or in molar 
concentrations are commercially available and the different assays are to a various degree 
dependent on the apo(a) size (104, 105).  
The use of a standardized, size independent method, traceable to an international reference 
material is desirable for the Lp(a) measurement and the possibility to compare results from 
different studies (106, 107). In 1995, the International Federation of Clinical Chemistry (IFCC) 
initiated a project in collaboration with manufacturers to establish a reference material for 
standardization of Lp(a) assays. From this project a proposed reference material was suggested 
as a common calibrator (108, 109). To further evaluate the proposed reference material, it was 
 
 11 
used to calibrate 22 different assays and to assign a target value of the different assay 
calibrators. This revealed a good inter-assay coefficient of variation (CV) of 2.8 % for the 
reference material and inter-assay CV of 9-15 % for quality control samples. Hence the use of 
the proposed reference material has been recommended for an accurate calibration and 
standardization of Lp(a) assays. However, in patient samples the 22 different assays displayed 
different results and the impact of apo(a) isoform varied greatly between the methods (104).  
The IFCC standardized reference material is traceable to Lp(a) values in nmol/L. Other 
reference materials for mg/dL exists but these are not standardized to a common reference 
material and the use of a Lp(a) assay traceable in nmol/L to the IFCC reference material is 
preferred (106). Factors for conversion of Lp(a) between mg/dL and nmol/L have been 
proposed. The factors vary from 2.85 for a small apo(a) size to 1.85 for a large size and a mean 
factor of 2.4 have been suggested. However, factor for conversion are more or less imprecise 
depending on the apo(a) size and the use of conversion factors are very controversial (106, 110).   
1.5.5 Lp(a) and CVD 
The evidence for Lp(a) as a strong independent causal risk factor for CVD is convincing and 
has been extensively demonstrated in large genome wide association studies, mendelian 
randomization studies and several meta-analysis (97, 111-113). Lp(a) levels above the 80th 
percentile in the population, corresponding to 50 mg/dL (~120 nmol/L) in the Copenhagen 
general population study (81) indicate an increased risk for IHD, CAVD, and PAD (97, 99, 
102). The risk for myocardial infarction (MI) is elevated already at Lp(a) levels >30 mg/dL 
(~75 nmol/L) and increases with higher Lp(a) levels to almost 4-fold at Lp(a) levels >85 mg/L 
(~212 nmol/L) (114). Patients with extremely high Lp(a) levels (>180 mg/dL or >430 nmol/L) 
have equal lifetime risk for CVD as patients with heterozygous familial hypercholesterolemia 
(115). Hence, the 2019 ESC/EAS guidelines suggests that measurement of Lp(a) levels should 
be considered at least once in every adults life to identify those with extremely high Lp(a) levels 
that are at the highest risk (19).  
High Lp(a) levels has been shown to be associated with ischemic stroke in several meta-
analysis (94, 100, 116). The evidence is less extensive than for IHD and seems to be different 
depending on ethnicity (117). Since Lp(a) is suggested to possess proatherogenic properties an 
association with VTE could be assumed. Such association has been demonstrated in a meta-
analysis (101) but the results from prospective trials are diverse where some show that Lp(a) is 
an independent risk factor for VTE in adults (118), but others do not (119, 120).  
1.5.6 Lp(a) lowering therapies   
Although, the evidence for the importance of Lp(a) as a risk factor for CVD is accumulating the 
major question remains whether Lp(a) lowering therapies can reduce the CVD risk. There are 
currently no available treatments to exclusively lower the plasma Lp(a) levels and no clinical 
outcome trials have investigated the effect of Lp(a) lowering on CVD risk. Therapies that lower 
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the plasma Lp(a) levels have a positive effect on the total lipid profile it is difficult to discern 
the specific impact on CVD risk due to Lp(a) reduction. However, based on data from studies 
with treatments that also affect the Lp(a) levels, it has been estimated that by reducing plasma 
Lp(a) levels to <50 mg/dL 1 of 14 cases of MI and 1 of 7 cases of CAVD could be prevented 
(96). In a placebo controlled trial, treatment with a PCSK9-inhibitor reduced plasma Lp(a) 
levels approximately 20 % which corresponded to a clinically significant reduction in CVD 
events independently from LDL-cholesterol (121). Other studies have demonstrated that a large 
Lp(a) reduction (65.7-100 mg/dL or 154-240 nmol/L) is required for a clinically significant 
CVD risk reduction (115, 122). 
Whilst, traditional lipid-lowering therapies (e.g. stains, fibrates, and ezetimibe) have no or 
marginal effect on decreasing plasma Lp(a) levels, treatment with CETP-inhibitors and PCSK9-
inhibitiors can reduce the Lp(a) levels by 25-30 %, and lipoprotein apheresis by 25-40 % (123, 
124). A meta-analysis from different statin trials revealed that statin treatment might even 
elevate the plasma Lp(a) levels up to 24 %, and the effect seems to be most pronounced from 
atorvastatin (125).  
Novel therapies to exclusively lower plasma Lp(a) levels are emerging, and positive results 
from a hepatocyte specific apo(a) antisense nucleotide (AKCEA-APO(a)-LRx) have been 
demonstrated. In a randomized, double-blind, placebo-controlled trial the plasma Lp(a) levels 
were reduced up to 80 % in patients with established CVD after 6-12 months treatment with the 
AKCEA-APO(a)-LRx (126).  
1.6 ACUTE CORONARY SYNDROME (ACS)  
1.6.1 Definition and diagnosis of ACS  
ACS is the acute manifestations of IHD, including the diagnosis of unstable angina (UA) and 
acute myocardial infarction (AMI). The pathophysiology behind ACS is atherosclerotic 
changes, atherosclerotic plaque rupture or superficial plaque erosion, and thrombosis formation 
leading to an acute myocardial ischemia and myocardial injury (127, 128).  
ACS diagnosis is based on typical symptoms, electrocardiography (ECG) changes, and 
elevation of biomarkers. According to the fourth universal definition of MI (2018), the term 
myocardial injury should be used when there is at least one cardiac specific Troponin result, 
above the 99th percentile upper reference limit (URL) and is considered acute if there is rise or 
fall in cTroponin levels. AMI is defined when there is an acute myocardial injury with evidence 
for acute myocardial ischemia and i) a rise or fall in cTroponin levels and at least one value 
above the 99:th percentile URL and ii) at least one of; symptoms of myocardial ischemia; new 
ischemic ECG changes; development of pathological Q-waves; imaging evidence of ischemia 
or identification of coronary thrombus by angiography or autopsy. AMI is further divided into 
non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation infarction (STEMI) 
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depending on the observed ECG changes. In addition, different types of MI are defined where 
type 1 is the traditional MI caused by ischemia in the myocardium due to plaque rupture and 
thrombosis formation. Type 2 MI is due to imbalance in oxygen demand and supply, for 
example caused by tachyarrhythmia or heavy physical effort; type 3 is sudden death caused by 
MI; type 4 and 5 MI are procedure related caused by percutaneous coronary intervention (PCI) 
(4a), stent thrombosis (4b) or by coronary artery bypass graft (CABG) (type 5) (127, 129, 130). 
UA are defined as “myocardial ischemia at rest or minimal exertion in the absence of 
cardiomyocytes necrosis” (131). The prevalence of UA has changed during the years and 
especially when cTroponins replaced the previously used less specific and sensitive biomarkers. 
After the introduction of high sensitive cTroponins analyses the diagnosis for UA has decreased 
since those patients are diagnosed with NSTEMI instead (131-133).  
1.6.2 Biomarkers for ACS  
 
Previously, unspecific biomarkers like aspartate transaminase, lactate dehydrogenase, 
myoglobin, creatine kinase, and the MB isoform of creatine kinase (CKMB) was used in the 
diagnostics of ACS but today the high sensitive cTroponins are the preferred biomarkers. In 
order to improve the sensitivity and specificity of cTroponins and the prognosis of the disease 
other additional biomarkers for ACS have been suggested. Frequently discussed are for example 
heart-type fatty acid binding protein, natriuretic peptides, soluble suppressor of tumorigenicity 
2, and growth differentiation factor 15. None of them have proven to outperform or add value to 
high sensitive cTroponin in the diagnosis of ACS and only CKMB and copeptin seem to be 
relevant so far (2, 130, 131, 134). 
 
Troponin was first described in the 1960:s and has since then remarkably changed the diagnosis 
of ACS (135). Troponins are important mediators int the thin muscle filament contractions in 
striated and cardiac muscle tissues. Three different types of Troponins exist, Troponin T that 
attaches the troponin complex to actin, Troponin I that inhibits the interaction between actin and 
myosin when calcium is not present, and Troponin C that reduces the Troponin I inhibition of 
myosin after binding to calcium, leading to muscle contraction. Cardiac specific isoforms of 
Troponin T and Troponin I exists, but not for Troponin C. The cTroponins are mainly bound to 
the thin filaments, and only a small fraction (3 %) is free in the cytoplasm. After a cardiac 
injury, the cytoplasmic cTroponins are rapidly released, followed by a later release of the 
structural bound troponins (136). Peak levels are seen after 10-12 hours, the half-life of 
cTroponin is approximately 2 h and increased levels can be detected up to 14 days after onset of 
disease. The kinetics between cTroponin I and Troponin T are slightly different, where 
cTroponin I reaches a higher peak-level and returns faster to the normal level, probably due to 




A rise or fall in cTroponin levels indicates an acute myocardial injury, while a more stable 
elevation of cTroponin is seen in many different conditions (e.g. heart failure, pulmonary 
embolism, critical illness, sepsis, aortic dissection, myocarditis, kidney failure) (131, 135). To 
clarify a rise or fall in cTroponin levels, repeated testing is recommended in a suspected ACS. 
Different algorithms and cut off levels have been suggested for rule-in or rule-out ACS. A 0/3-
hour- and a 0/1-hour algorithm is presented in the 2015 ESC guidelines. In the 3-hour algorithm 
a first blood test is collected at entry into the emergency room (ER) and a second test 3 hours 
later. An ACS is likely if there is a change in cTroponin levels and at least one result over the 
upper reference limit. In the 1-hour algorithm, an initial very low level of cTroponin can rule-
out ACS directly, otherwise a second cTroponin is measured after 1 hour. ACS can then be 
ruled-out if there is an initial low level with no change after 1 hour or ruled-in if the 1-hour 
value is elevated and show a change from the first measurement. The exact cut-off levels and 
delta changes of cTroponin are assay dependent (131). In patients with elevated cTroponin 
levels due to other causes, these algorithms to rule-in or rule-out of ACS cannot be used and the 
interpretation of cTroponin levels is more difficult.  
 
CKMB, the MB isoform of CK is not specific for myocardium but is the most abundant isoform 
found in cardiomyocytes. CKMB have a faster clearance than cTroponin and returns to normal 
levels within 48-72 hours after an ACS. Before the introduction of cTroponins, this was the 
biomarker of choice for diagnosing ACS, but today it is due to the rapid clearance, most useful 
in the diagnosing of an early reinfarction (131).  
 
Copeptin is derived from the c-terminal part of the pre-prohormone of vasopressin (i.e. 
antidiuretic hormone). It is released in proportional manner to vasopressin but is more stable in 
the circulation and easier to measure. Copeptin levels rises early in multiple acute conditions as 
an indicator of endogenous stress (139-141). Even if not specific, copeptin has been suggested 
as an additional biomarker in diagnosis of AMI and seems to add value to conventional 
cTroponin assays for the early rule-out of AMI (142-145). However, in combination with the 
high sensitive cTroponin assays, the additional value of copeptin is more uncertain (146-148). 
Hence, the use of copeptin is only recommended for early rule-out of AMI when high sensitive 











2 OBJECTIVE   
2.1 OBJECTIVE OF THE THESIS  
The objective of the thesis is to evaluate new potential biomarkers to improve the diagnosis and 
management of cardiometabolic diseases. An additional aim is to establish an efficient process 
for rapid transfer of new potential biomarkers, identified in discovery studies into evaluation in 
the routine care setting.  
The thesis contains four studies in different patient cohorts, characterized of separate designs, 
reflecting diverse phases in the implementation process of biomarkers for cardiometabolic 
diseases (Figure 1). 
Figure 1. Overview of the strategy to implement new biomarkers and how the four separate 






2.2 SPECIFIC OBJECTIVES IN THE DIFFERENT PAPERS 
Paper I  
To investigate the distribution of plasma Lp(a) levels and its association with mortality and 
CVD in a large cohort of patients that had their plasma levels of Lp(a) determined in routine 
care.  
Paper II  
To investigate the importance of plasma Lp(a) levels as a risk factor for CVD and its association 
with metabolic control in patients with type 1 diabetes.  
Paper III 
To establish an efficient process for rapid transfer of potential new biomarkers, identified in 
discovery studies into evaluation in the routine care and to define a concept for inclusion of 
patients and biobanking in the acute care setting. This is prototyped by the evaluation of 
chemokine ligand 16 (CCL-16) as a potential new biomarker for ACS.  
Paper IV 
To study in detail how the lipoprotein metabolism is affected by simvastatin and ezetimibe 
treatment, alone or in combination, in order to gain further understanding of the molecular 





3 CLINICAL RELEVANCE  
The healthcare is facing a great challenge with an extensive burden of cardiometabolic diseases 
worldwide. New knowledge about the pathophysiological processes have been obtained and 
important research discoveries have improved management of the diseases. Despite that, 
cardiometabolic diseases is a growing health issue in the population and the prognosis, 
diagnosis, and treatments needs to be further improved. In this process, discovery and 
implementation of additional biomarkers is extremely relevant and can contribute to better 
medical care of the patients.  
New advancing technologies have increased the possibilities to discover new potential 
biomarkers but the process from discovery into implementation in the clinic is still long and 
challenging. Very few biomarkers survive all the way through, and a more efficient process is 
desirable.  
In Paper III we present our approach for an efficient transfer of a new potential biomarker, 
identified in a discovery project into early evaluation in the routine care setting. The study 
contributes with further understanding of the process and the important considerations that must 
be made in biomarker studies. In addition, we define a lean process for inclusion of patients and 
biobanking of samples in acute care settings.  
The use of high sensitive cTroponin assays has greatly improved the diagnostics of ACS but 
additional biomarkers to further increase sensitivity and specificity for early diagnosis are still 
desirable. Furthermore, in patients with suspected UA and no elevation of cTroponin or with 
raised levels for other reasons, additional biomarkers could help to distinguish UA from other 
conditions. In Paper III the transfer of a biomarker from discovery into evaluation in the 
routine care setting is prototyped by the evaluation of CCL-16. This chemokine was suggested 
as an interesting biomarker for ACS in a discovery project called Vinncardio, initiated by the 
Science for Life Laboratory, Royal Institute of Technology (KTH), Stockholm, Sweden. In the 
discovery project, high-throughput affinity plasma proteomic technologies were used to screen 
existing biobanks for new potential biomarkers for CVD and we evaluated whether CCL-16 
could add value to hs-Troponin T in the diagnosis of ACS in the routine care setting.  
High Lp(a) levels is a risk factor for CVD but it is yet not known whether the elevated risk can 
be reduced by Lp(a) lowering therapies. Despite that, further knowledge of the role of Lp(a) and 
its association with CVD in different populations and diagnoses are needed to better understand 
when Lp(a) should be measured and how patients with elevated Lp(a) levels should be 
managed. In Paper I and Paper II, we examine the role of Lp(a) as a risk factor for CVD in a 
large cohort of patients that had their plasma Lp(a) levels determined in the routine care and in 
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patients with type 1 diabetes to further understand the importance of high Lp(a) levels in 
different patient groups.  
The management of dyslipidemias has improved over the years for several reasons. The 
treatment options have increased and new therapies e.g. ezetimibe and PCSK9-inhibitors have 
been added to the selection of treatments. The diagnosis of dyslipidemias has been developed 
due to additional biomarkers and the introduction of enhanced laboratory assays with better 
performance. Despite that, there is still a need for improved individual risk assessment and 
optimization of treatment in patients with dyslipidemias. A deeper understanding of the 
different biomarkers, their contribution to the overall CVD risk, and how they can be used to 
better characterize the dyslipidemia can contribute to this.  
Previously the SHARP and IMPROVE-IT trials have shown additional reduction of 
cardiovascular events when ezetimibe was added to simvastatin treatment. The effect was most 
pronounced in patients with type 2 diabetes where the dyslipidemia is characterized by elevated 
remnant-particles, increased small dense LDL-cholesterol particles, and low HDL-cholesterol 
levels. Remnant-cholesterol is an independent risk factor for IHD, also promoting and 
sustaining low grade inflammation, and is an interesting biomarker for CVD risk assessment. In 
Paper IV we study in detail how treatment with simvastatin and ezetimibe, alone or in 
combination, affect the lipoprotein metabolism to further understand the molecular effects 
behind the additional atheroprotective effects observed in the SHARP and IMPROVE-IT trails, 







This section provides an overview of the different patient cohorts and methodologies used in 
the separate studies. A more detailed description is found in the respective papers.   
4.1 DESCRIPTION OF THE DIFFERENT COHORTS 
Paper I is a retrospective observational registry based cohort study where the distribution of 
plasma Lp(a) levels and its association with mortality and CVD were investigated in 23 398 
patients (11 238 males and 12 160 females, mean±standard deviation (SD) age 55.5±17.2 
years) that had their Lp(a) levels measured in the routine clinical chemistry laboratory at 
Karolinska University Laboratory (KUL) between 2003-2017. The Lp(a) results were 
retrieved from the laboratory database together with other laboratory test results of interest. 
The laboratory data was linked to register data retrieved from the National Board of Health 
and Welfare registers (causes of death, prescribed drugs, National patient register) and 
National Quality registers (Swedeheart, The Swedish Stroke-register).  
The patients were referred from totally 1442 different units and almost 30 % were from the 
specialties of cardiology, vascular surgery and endocrinology. The indication for Lp(a) 
measurement is not known and are probably diverse depending on the referring unit. 
However, all measurements were for some reason performed in patients in the routine care 
and in many cases probably as part of CVD risk estimation. Hence, it is tempting to speculate 
that the overall CVD risk may be higher in this cohort compared to the general population. 
Within the cohort, 19.1 % of the patients had a previous CVD and this is similar to what is 
expected in the Swedish general population where approximately 2 million (~20 %) people 
have CVD (16). However, our definition of previous CVD is more limited and with a more 
general definition the prevalence might be even higher. Two major risk factors for CVD, i.e. 
hypertension and diabetes were present in 41.1 % and 18.5 % of the patients respectively. 
That is higher than the estimated prevalence of hypertension (27 %) and diabetes (5 %) in the 
general Swedish population (statistics from (150) and Swedish National Diabetes Register, 
March 2020). Of the patients, 33.5 % were treated with a lipid lowering drug and 24.2 % had 
a diagnosis of hyperlipidemia in the National patient register, but the prevalence is probably 
slightly higher due to missing registrations of the diagnosis.  
Paper II is an observational cross-sectional registry study where the importance of plasma 
Lp(a) levels as a risk factor for CVD and association to metabolic control were investigated 
in 1860 patients (mean±SD age 48±16 years, diabetes duration 27±15 years and HbA1c 
62±14 mmol/mol) with type 1 diabetes. All included patients received regular care at the 
metabolism unit at Karolinska University Hospital and had their Lp(a) levels measured in the 
clinical routine at least once. Laboratory test results were retrieved from the laboratory 
database at KUL. Information about treatment, other diagnosis, and complications were 




In Paper III, patients eligible for inclusion were identified when their plasma samples were 
analyzed for hs-Troponin T at KUL. The automatic laboratory system was for 9 months 
programmed to save the remaining plasma from all samples referred to KUL from the ER, 
acute care unit or the cardiac intensive care unit for measurement of hs-Troponin T. The 
samples were temporarily stored for 2 months and meanwhile, a letter was sent to 4924 
patients with information about the study and an invitation to participate. A signed informed 
consent form was returned within two months from 1986 (40.3 %) of the patients. For all 
others the temporarily stored plasma samples were discarded and all their information 
permanently deleted from the study. Including 291 patients recruited directly at the ER, a 
total of 2277 patients were possible to include. Unfortunately, 646 patients were excluded due 
to missing samples and/or information, insufficient sample volume or laboratory errors 
(including extensive hemolysis in the plasma samples) and finally 1631 patients (956 males 
and 671 females, mean±SD age 63.1±16.5 years) were included. The diagnosis from the 
hospital admission were retrieved by manual reviewing the electronic medical records at 
Karolinska University Hospital.  
Repeated hospital admission occurred for 146 patients during the study inclusion time, and 
plasma sampled from 1777 hospital admissions with the diagnosis distributed between angina 
(n=28, 1.6 %), UA (n=18, 1.0 %), NSTEMI (n=52, 2.9 %), AMI (n=47, 2.6 %), and any other 
diagnosis (n=1632, 91.8 %) were included. It is estimated that 5 % of all patients appearing 
with chest pain in the ER suffer from ACS (151). The slightly higher frequency of ACS (6.6 
%) in our cohort can be due to the fact that patients from the cardiac intensive care unit were 
also included or that patients with ACS were more motivated to participate in the study.  
Paper IV is a randomized case-control study where forty patients with uncomplicated 
gallstone disease, eligible for elective cholecystectomy at the Department of Surgery, 
Danderyd Hospital, Sweden were included. The patients (14 males, 13 fertile females and 13 
postmenopausal females) were randomized to four-week treatment before surgery to placebo, 
simvastatin (80 mg daily), ezetimibe (10 mg daily), or to the combination of both simvastatin 
and ezetimibe. Fasting blood samples were collected before treatment start and at the end of 
study. During the surgical intervention, liver biopsies and bile were collected.  
4.2 LABORATORY ASSAYS  
4.2.1 Routine laboratory parameters  
Routine laboratory parameters were measured with certified routine assays at KUL. For hs-
Troponin T, the Elecsys hsTroponin T assay from Roche (Roche Diagnostics, GmbH, 
Mannheim, Germany) was used. The eGFR was calculated from the revised Lund-Malmö 
formula (152). LDL-cholesterol was calculated from the Friedewald’s formula if TG was < 




In Paper I, Lp(a) was measured at KUL by two different particle enhanced immunoassays. 
Before 2014 an assay that reported Lp(a) in mass concentration (Tina-quant Lipoprotein(a), 
Roche Diagnostics) was used. From 2014 an assay that reported Lp(a) in molar concentration 
(Tina-quant Lipoprotein(a) Gen 2, Roche diagnostics), standardized to the IFCC reference 
material (SRM 2B) was used. In Paper II all Lp(a) results were analyzed with the assay 
reporting in molar concentration, except from 5 % of the patients that had their Lp(a) levels 
measured in other laboratories, using other certified Lp(a) assays (Lp(a) Ultra Sentinel 
Diagnostics, Beckman Coulter or Lp(a) Advia XPT, Siemens Heathcare) that report values in 
mass concentration.  
Since two different assays for Lp(a) measurement were used in Paper I, the different results 
in mg/dL or nmol/L were analyzed separately or divided into quartiles to be able to compare 
outcomes between quartile levels of Lp(a) for mg/dL and nmol/L together. As discussed 
previously, the conversion of Lp(a) values between nmol/L and mg/dL are controversial since 
the assays are not comparable and the conversion is more or less imprecise depending on 
apo(a) isoform size. Hence, we consider that a conversion may have an impact on the results 
from this study and decided not to use that approach. However, the results measured with an 
alternative assay in Paper II were converted into nmol/L before statistical analysis by the 
conversion factor [Lp(a) nmol/L= 2.4 x (Lp(a) mg/dL)] suggested by Roche Diagnostics and 
Brown et. al. (110) since we considered that these values were too few to have an major 
impact on the final results. 
4.2.3 CCL-16 
CCL16 was measured with either an enzyme linked immunosorbent assay (ELISA) assay 
(CCL16 (human) ELISA kit, catalog number KA1724, Abnova, Taipei, Taiwan) performed 
with an automatic system (Freedom EVO 200, Tecan Trading AG, Switzerland) or on a 
Luminex MAGPIX® instrument with an antibody suspension bead array as described (153).  
4.2.4 Lipoproteins and apolipoproteins  
Lipoproteins were separated by size-exclusion chromatography and the cholesterol and TG 
content in the VLDL, LDL and HDL fractions were determined as described earlier (154). 
Nuclear Magnetic Resonance spectroscopy (NMR) were used for a detailed analysis of 
lipoprotein subclasses, ApoA1 and ApoB at Nightingale Health Ltd. Laboratory, Vantaa, 
Finland (155).  
4.2.5 Proteoglycan binding  
The binding affinity of apoB-containing lipoproteins to human arterial proteoglycans (PG) 
was assessed by a solid phase procedure that has been described earlier (156, 157).  
 
22 
4.2.6 Messenger ribonucleic acid (mRNA) expression in liver biopsies  
Total ribonucleic acid (RNA) was extracted and transcribed into complementary 
deoxyribonucleic acid (cDNA) using Omniscript (Qiagen, Sollentuna, Sweden). For the 
quantification of mRNA levels, SYBRGreen mastermix and specific primers were used, 
arbitrary units were calculated by linearization of the cycle threshold, i.e. CT values and 
normalized to glyceraldehyde-3-phosphate-dehydrogenase.  
4.3 STATISTICAL ANALYSIS   
The statistical analysis was performed as described in detail in the separate papers and are 
only briefly explained here. 
Binary variables are presented as positive counts and percentages. Numerical variables are 
presented as mean±SD if normally distributed or median (inter quartile range (IQR)) for 
variables with skewed distribution (Paper I, II and III). In Paper IV data are expressed as 
mean±standard error of the mean unless otherwise stated.   
Differences in means were compared by two-sided t-tests (Paper I-III) or paired t-test 
(Paper III), Wilcoxon-Rank sum-test for differences in medians (Paper II), and Pearson´s 
chi-squared test for proportions (Paper II). In general, a p-value < 0.05 was considered 
significant (Paper I-IV).  
The patients in Paper I were divided into quartiles of Lp(a) levels in mg/dL and nmol/L 
respectively. All-cause mortality, CVD related mortality, and time to CVD events were 
analyzed across the Lp(a) quartiles using Cox proportional hazard regression models adjusted 
for age, sex, smoking, diabetes, hypertension, LDL-cholesterol, statin treatment, and previous 
CVD.  
In a subgroup analysis on time to IHD, patients with Lp(a) levels in the 4th quartile were 
compared to the 1st quartile using Cox proportional hazard models for each defined baseline 
characteristic or category and fitting adjusted models including an interaction term between 
the two Lp(a) quartiles and the respective binary variable. A p-value < 0.01 was considered 
significant for interaction according to the Bonferroni correction.  
The cohort were also divided into seven age groups and the median, 80th, and 90th percentile 
levels of Lp(a) were compared between the groups using quantile regression.   
The reason why the median, 80th, and 90th percentile Lp(a) levels are compared in Paper I 
and Paper II is that i) Lp(a) has a skewed distribution, hence the median is preferred in front 
of the mean, ii)) Lp(a) levels above the 80th percentile in the population have been discussed 
as an indicator for increased risk (98) and therefore the 80th percentile levels in this cohort 
were investigated, iii)) patients with extremely high Lp(a) levels (> 180 mg/dL or > 430 
nmol/L) are at highest CVD risk and consequently the extreme Lp(a) levels in this cohort 
were examined (19).  
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In Paper II the patients were divided into four groups according to their Lp(a) levels in 
nmol/L: very low <10, low 10-30, intermediate 30-120, and high >120. Crude and adjusted 
relative risk ratios (RRR) for the different complications were calculated using multinomial 
logistic regression models. The categorical variable of Lp(a) group was the dependent 
variable and the binary variable of the complication was the independent variable. In the 
adjusted models age and smoking status were covariates.  
The median, 80th, and 90th percentile levels of Lp(a) were estimated in the different quartiles 
of age and in three groups of HbA1c levels by quantile regression models. Differences 
between the age quartiles or HbA1c groups were explored by Wald test.  
In Paper III, differences in CCL-16 levels between the diagnosis at hospital admission was 
compared by one-way analysis of variance (ANOVA). Possible correlations between CCL-16 
and hs-Troponin T or eGFR were explored by simple linear regression.   
Significances in Paper IV were tested by multi-way ANOVA and post hoc comparison were 
performed according to the Fisher´s least significant difference test.   
Statistical analyses were performed with Stata version 15 (StataCorp, College Station, TX, 
USA) (Paper I-II), IBM SPSS Statistics 26 (IBM Corporation) (Paper III) or Statistica 
version 12.0 (StatSoft, Tulsa, OK, Data S1) (Paper IV). Graphical presentations in Paper I-




5 ETHICAL CONSIDERATIONS 
All studies were approved by the Swedish Ethical Review Authority (Paper I: 2017/871-31/4 
and 20181526-32; Paper II: 2017/872-31/4; Paper III: 2015/1570-31/4 and 2016/372-32; 
Paper IV: 2006/1204-31/1). Paper IV was also approved by the Swedish Medical Agency 
and registered in the EU clinical trial register (EudraCT number: 2006-004839-30) 
We have had comprehensive ethical and juridical considerations in the different projects and 
extensively discussed juridical aspects of the study designs with the relevant authorities at 
Karolinska Institutet and Karolinska University Hospital. This has provided a deeper 
understanding of the complexity in these issues and therefore the ethical considerations 
deserve an extended section.  
5.1 GENERAL ETHICAL CONSIDERATIONS WITHIN RESEARCH PROJECTS  
The basic ethical principles, i.e. the principle of respect for autonomy and integrity, the 
principle of beneficence and do not harm, and the principle of justice are fundamental for 
ethical considerations in research projects and will be discussed in general first.  
The principle of respect for autonomy and integrity means that all individuals are autonomous 
with the right to decide for their own life. In research, this refers to that the individual must be 
fully informed about the project and potential risks, and able to autonomously decide about 
participation. It is always voluntary to participate and discontinuation in the study is allowed 
at any time without explanation or disadvantage in the future care. The study subjects give 
the researcher a confidence to use their personal data, medical information, samples or bodies 
for research, and the researcher should manage this with respect for the individual’s integrity. 
Unnecessary handling of personal data should be avoided, the data should be handled safely, 
and protected from unauthorized access.  
According to the principle of beneficence and do not harm, the research should not be 
performed on expenditure of others, all possible risks must be minimized, the research should 
be of high quality, and beneficial for everyone. Before initiating a research project, it must be 
considered whether the possible gains can motivate the research and interventions needed, 
and if the benefits outweigh the potential risks. During the study, the patients should be 
monitored safely, the investigations must be of high quality, and biological samples should be 
properly stored to keep the material intact and give true results. A study design of good 
quality favors correct results and avoidance of biased data.  
Finally, the principle of justice means that research must be fair in design, selection of study 
participants, and performance. Everyone must be equally treated in all ethical aspects 
independent of age, gender, socioeconomic status etc.  
Except from these basic ethical principles, there are many more aspects, including both 
general human rights, moral- and ethical principles and laws. Several guidelines, consensus 
documents, and recommendations exist. One very important is the Declaration of Helsinki, a 
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statement of ethical principles for medical research involving human subjects adopted by the 
World Medical Association. Another is the Good Clinical Practice guidelines for performing 
clinical trials in human subjects from the International Council for Harmonization of 
Technical Requirements for Pharmaceuticals for Human Use. The Swedish research council 
has also written a document about “Good research practice” that discusses guidelines, laws 
and important considerations in ethics.   
In addition, all research in Sweden involving humans must be approved by the Swedish 
Ethical Review Authority. This is regulated by the Act concerning ethical review of research 
involving humans (SFS 2003:460). Several other laws are also important, i.e. the Patient data 
act (Patientdatalagen, SFS 2008:355), the Act of biobanking (SFS 2002:297) and the Health 
data act (SFS 1998:543). From the 25:th of May 2018 the General Data Protection Regulation 
(GDPR, EU 2016/679) replaced the personal data ordinance. The GDPR is a European Union 
regulation concerning the protection of natural persons and the handling, processing, and 
movement of personal data.  
5.2 SPECIFIC ETHICAL CONSIDERATION IN THE DIFFERENT PAPERS 
Paper I is a register-based study, where more than 23 000 patients were identified from a 
database at KUL. Only register based data are handled in this study and the individual 
subjects are not informed and asked for participation. According to Art. 89 in GDPR there is 
an exception for handling of registry based personal data for scientific research purposes, 
meaning that all participating subjects do not have to be informed if not feasible, provided 
that the data are handled safely, and according to the principle of data minimization, 
including pseudonymization if possible. This makes it feasible to perform register-based 
studies involving many thousands of subjects and studies where some of the subjects are 
deceased.  
All personal data from KUL and the different registers were merged by the National Board of 
Health and Welfare by matching of the Swedish personal identification number. The data was 
then coded into a study ID before it was presented to the investigators and exclusively 
pseudonymized data are handled in the study. The key for this code is kept by the National 
Board of Health and Welfare and only the responsible investigators can by special request 
access this key, that will be permanently destroyed after three years. Pseudonymized data 
should be handled as carefully as personal data and there is a great responsibility for the 
investigators to make sure of this.  
In a future second part of this project, patients with high Lp(a) levels will be investigated in 
more detail, additional data will be requested from the patients, and collected from their 
electronic medical records. For this purpose, during Spring 2018, a letter with information 
about the study and an invitation to participate in the second part of the project was sent to 
more than 4000 patients from our cohort with Lp(a) levels >125 nmol/L. Of these, 42 % 
accepted to participate and returned a signed informed consent form. This approach to recruit 
patients poses a dilemma since the patients receive a letter from the investigators without 
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their permission to be contacted, and this may be perceived as a violation to their privacy. 
Before initiation of the study we had a comprehensive discussion with the lawyers at 
Karolinska Institutet about the study design and in fact, one of the respondents felt offended 
and questioned our right to contact them. We performed the study before the current GDPR 
law was introduced in May 2018. According to the GDPR, this approach would not be 
possible unless specific enquiry to the data protection authorities whether the unique study 
objectives allow the investigating doctors to directly contact patients, bypassing their treating 
doctors.  
In Paper II, all participants were patients at the Department of Endocrinology, Karolinska 
University Hospital Sweden and the study only include existing information from the 
electronic medical records. No additional data were requested, and no interventions were 
performed. Therefore, the patients were not asked individually for participation in the study.  
Potential privacy concerns were minimalized due to careful data management, ensuring that 
no unauthorized persons could access it. The data were collected from the electronic medical 
records by the investigators, all physicians with professional secrecy working at the 
Karolinska University Hospital. The data were thereafter coded into a given study ID and no 
one except from the investigators had access to the securely stored key. After finishing the 
study, the key was discarded and only the anonymous data was stored. The data are presented 
at group level so that no individuals can be identified.  
In Paper III subjects eligible for inclusion were identified when their plasma samples were 
analyzed for hs-Troponin T at KUL. The plasma samples were temporarily stored for a 
longer time than usual and a letter with an invitation to participate in the study was sent to the 
patients’ home, without their permission to be contacted. To minimize the risk of interfering 
with privacy, a letter was only sent once without any reminders. If no reply was received 
within the time limit, all information about the patient were permanently deleted from the 
study. The plasma samples were securely stored temporarily in the routine laboratory and 
discarded without any additional analyzing if the patient did not participate in the study.    
It is a challenge to recruit patients with an acute medical condition. On the other hand, it can 
be unethical to not perform research aiming to improve the management of patients with 
acute diseases due to the difficulty. It is important to make sure that the patient understands 
that participation is voluntary and that their future care will not be affected if the patient 
disagrees to participation. This can be difficult in the acute care and a patient with an acute 
medical condition may not be capable to give an informed consent for participation or the 
inclusion procedure might delay the routine care. Therefore, our approach to use the routine 
blood samples and contact the patients and ask for participation afterwards is appealing. Also 
here, with the new GDPR legislation an enquiry about the feasibility of this kind of study 
should be a priory discussed with the data protection authorities, as described above for 
Paper I.  
In Paper IV, the patients received written and oral information and were invited to 
participate in the study at a screening visit by the doctor or a nurse. A personal meeting is 
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positive to make sure that the patient has fully understood the information and are able to ask 
questions. On the other hand, it can be more difficult to refuse participation and a time for 
consideration is important to offer. 
Any additional intervention in a study, beyond the routine care may involve an increased risk. 
In Paper IV the patients were treated with simvastatin and ezetimibe, additional blood 
sampling as well as liver biopsies and collection of bile during laparoscopic cholecystectomy 
were performed. Whether the possible benefits from the study outweighed the potential risks 
were carefully considered. To minimize the risks the patients were closely monitored, and the 
surgery was performed by experienced surgeons. In addition, the patients were fully informed 
about the study and the risks and were free to end their participation at any time without any 






6 RESULTS AND DISCUSSION 
6.1 PAPER I  
6.1.1 Distribution of plasma Lp(a) levels 
Plasma Lp(a) levels had a skewed distribution with median 15.9 mg/dL or 18,2 nmol/L, 80th 
percentile at 55.6 mg/dL or 113.5 nmol/L, and 90th percentile at 89.2 mg/dL 179.5 nmol/L 
(Figure 2).  






Lp(a) levels increased with increasing age and up to ~1.4 times higher mg/dL and ~1.7 times 
higher nmol/L median, 80th, and 90th percentile levels were observed in all age groups above 
51 years compared to the reference age group 21-35 years. In the age group 36-50 years the 
Lp(a) nmol/L median, 80th, and 90th percentile levels were also significantly increased. (Data 
shown in Table 2, Paper I.)  
The median Lp(a) levels were 11-12 % higher in females in the total cohort, and when 
compared in different age groups, significantly higher Lp(a) levels were generally observed 
in females in the age groups above 51 years, but not in the younger. (Data shown in Figure 3 
and supplementary Table S4, Paper I.) The median and 95 % Confidence Interval (CI) Lp(a) 
mg/dL and nmol/L levels for males and females in different age groups are shown in Figure 
3.  




Postmenopausal females seem to have higher Lp(a) levels than premenopausal (158, 159) and 
this could explain why age and sex influenced Lp(a) especially after 51 years of age. Hence, 
we compared the levels in females >51 years (i.e. mean age for menopause in Sweden) or 
with hormone replacement therapy (HRT) to females ≤51 years and no HRT and the two 
former had significantly higher Lp(a) levels (p<0.01 for all). (Data shown in Table 3, Paper 
I.) This reinforces the assumption that menopausal status affect Lp(a) in this cohort and 
indicate a hormonal influence on Lp(a) levels. In line with this, a meta-analysis showed 
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reduction of plasma Lp(a) levels in females receiving HRT and oral administration was more 
effective than transdermal (160). In two other studies, Lp(a) levels in males decreased by 30 
% after oral administration of estrogen (161), but was unchanged after parenteral 
administration (162), and the effect from HRT seems to be dependent on the administration. 
Whether this hormonal influence on plasma Lp(a) levels is clinically relevant and can have an 
impact on the Lp(a) associated CVD risk needs to be further investigated in other studies.  
6.1.2 Lp(a) levels and association with mortality and CVD 
Patients with Lp(a) levels in the 4th quartile had increased Hazard Ratio (HR) of 1.18 (95% 
CI 1.04-1.35, p=0.012) for CVD (i.e. IHD and stroke), and 1.36 (95% CI 1.14-1.61, 
p=0.001) for IHD compared to patients with Lp(a) levels in the 1st quartile. No association 
between Lp(a) levels and stroke was observed and the increased CVD risk seems to be 
mainly due to IHD. (Data shown in Figure 4, Paper I.) 
Age, previous CVD, diabetes, and LDL-cholesterol did not interact with the IHD risk in a 
subgroup analysis comparing patients with Lp(a) levels in the 4th to the 1st quartile in each 
defined subgroup category. However, sex had a significant interaction (p=0.005). (Data 
shown in Figure 5, Paper I.) There was no difference in age between males and females with 
Lp(a) levels in the 4th quartile, but the number of females were higher and the extremely high 
Lp(a) levels (i.e. indicating the highest CVD risk) were more frequent in females. Coherent 
with this, higher plasma Lp(a) levels in females with CVD have been reported in other 
studies (163, 164) and it has been suggested that Lp(a) is a stronger risk factor for CVD in 
females (163-165). However, the influence of sex on the Lp(a) associated CVD risk needs to 
be reviewed further.  
In summary, the distribution of plasma Lp(a) levels and the increased risk for IHD in this 
cohort of patients referred from hospitals, out-patient clinics or general practitioners in the 
Region Stockholm is comparable to what has been reported in general population studies (81, 
94, 97), demonstrating that elevated Lp(a) levels is also a risk factor of importance in this 
cohort.  
6.2 PAPER II 
6.2.1 Distribution of plasma Lp(a) levels 
The plasma Lp(a) levels had a skewed distribution with median, 80th, and 90th percentile 
levels of 19, 98, and 176 nmol/L, and no difference between males and females. Lp(a) levels 
increased with age, and patients in the 3rd and 4th quartile of age (49-59 and 60-90 years, 
respectively) had approximately 1.5 times higher median, 80th, and 90th percentile levels 
compared to patients in the 1st age quartile (18-35 years).  
6.2.2 Lp(a) levels and vascular complications  
Patients with type 1 diabetes and high Lp(a) levels (>120 nmol/L) had, adjusted for age and 
smoking, a RRR of 1.51 (95% CI 1.01-2.28, p=0.048) for any macrovascular complication 
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(i.e. composite CVD of coronary heart disease (CHD), cerebrovascular disease, and 
diabetic foot ulceration), a RRR of  1.68 (95% CI 1.12-2.50, p=0.01) for albuminuria, and a 
RRR of 2.03 (95% CI 1.02-4.01, p=0.043) for CAVD compared to patients with very low 
levels (<10 nmol/L). The unadjusted RRR for CVD was 2.2 (95% CI 1.37-3.52, p=0.001) 
and for CHD 2.42 (95% CI 1.41-4.15, p=0.001), but this was no longer significant after 
adjustment (Figure 4). The association between Lp(a) levels and all vascular complications 
investigated are showed in Table 2, Paper II. 
Figure 4. RRR for vascular complications in patients with type 1 diabetes and high (>120 
nmol/L) compared to very low (<10 nmol/L) Lp(a) levels   
 
*p<0.05, **p<0.01. Adjusted for age and smoking status. CVD: cardiovascular disease, CHD: coronary 
heart disease, Composite CVD: CHD, cerebrovascular disease and diabetic foot ulceration, CAVD: calcified 
aortic valve disease.  
As far as we know, this is the largest study investigating the association between Lp(a) and 
vascular complications in patients with type 1 diabetes. Nevertheless, it is limited in size, 
CVD events were only present in 9 % and this constrains the ability to thoroughly 
investigate possible associations between Lp(a) levels and subcategories of CVD (i.e. CHD 
or cerebrovascular disease). However, consistent with our results, patients with type 1 
diabetes had an increased risk for CVD at Lp(a) levels >30 mg/dL (~75 nmol/L) in a small 
prospective study (166), and a trend for positive correlation between Lp(a) and albuminuria 
were demonstrated in children with type 1 diabetes (167). High Lp(a) levels has been 
identified as a risk factor for CAVD across multiple ethnicities (99), but the relevance as a 
risk factor in patients with type 1 diabetes has not been investigated before, and this is a 
novel finding. In conclusion, high Lp(a) levels was a significant risk factor for 
cardiovascular complications in this cohort of patients with type 1 diabetes, and assessment 
of Lp(a) levels can improve the risk estimation also in this group of patients.  
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6.2.3 Lp(a) levels in relation to metabolic control  
Plasma levels of Lp(a) were associated with metabolic control. Patients with intermediate 
metabolic control (HbA1c 52-70 mmol/mol) had higher 80th and 90th percentile Lp(a) levels 
(p<0.05 and p<0.001) and patients with poor metabolic control (HbA1c >70 mmol/mol) had 
higher median and 90th percentile Lp(a) levels (p<0.01 and p< 0.001) compared to patients 
with good metabolic control. The risk to have high (>120 nmol/L) compared to very low 
(<10 nmol/L) Lp(a) levels were ~1.8-fold increased (RRR 1.78, 95% CI 1.15-2.76, p=0.01) 
for patients with poor metabolic control and ~1.5-fold increased (RRR 1.49, 95% CI 1.01-
2.18, p=0.043) for patients with intermediate metabolic control compared to good metabolic 
control. (Data shown in Figure 2A-B, Paper II.) 
Influence of  metabolic control on Lp(a) levels has been observed before (168), but not in all  
studies (169, 170). In an investigation of patients with type 2 diabetes, the insulin levels were  
inversely correlated to the Lp(a) levels not regulated by genetic trait (171). Since Lp(a) levels 
probably are controlled mainly by its synthesis rate (172), this finding in patients with type 2 
diabetes together with our results might suggest that insulin has an influence on the hepatic 
Lp(a) metabolism. Future studies are needed to reveal such a possible mechanism further.   
6.3 PAPER III 
No significant differences in CCL-16 were observed between the different diagnosis of 
angina, UA, NSTEMI, AMI or any other diagnosis, neither between the composite of any 
ACS (UA, NSTEMI and AMI) and all other diagnosis. (Data shown in Figure 7, Paper III.) 
CCL-16 was identified as an interesting biomarker for ACS in the discovery study, but it had 
no additional value to hs-Troponin T when evaluated in a routine care setting. Several factors 
can contribute to the contradictive results as discussed in Paper III.  
In the discovery project, plasma samples collected in tubes containing potassium and the 
anticoagulant ethylenediaminetetraacetic acid (K2-EDTA) was used. For the evaluation of 
CCL-16 in the routine care, the plasma samples collected in tubes containing the 
anticoagulant Lithium (Li)-Heparin for measurement of hs-Troponin T was used. Therefore, 
measurement of CCL-16 in plasma samples collected in either of the two sample tubes was 
compared. The analytical performance with two different antibodies (HPA042909 and 
HPA051577) was lower in samples collected in tubes containing Li-Heparin compared to 
K2-EDTA (HPA042909 CV 39 % and 25 % respectively; HPA051577 CV 44 % and 29 %, 
respectively). In addition, the discrepancies between CCL-16 measured in plasma from Li-
Heparin and K2-EDTA tubes were significantly different between the two antibodies 
(p<0.01). (Data shown in Figure 2-3, Paper III.) Hence, the anticoagulants in the sample 
tubes influenced the measurement of CCL-16 differently, depending on the antibody used 
and possible also due to a matrix effect. Despite this, we estimated that this would not affect 
our experiments and decided to use plasma collected in Li-Heparin tubes for CCL-16 
measurements. Considering the contradictive outcomes from the discovery and the evaluation 
in the routine care setting, the matrix effect and the diverse performance of CCL-16 
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measurements between the sample types may still influence on the results. Therefore, it 
would be interesting to investigate CCL-16 differences between patients with ACS and other 
diagnosis in plasma collected in both types of tubes. The relative discrepancies between the 
diagnosis might be different depending on sample type and have an impact on the findings.  
A stability test revealed that CCL-16 was susceptible to the storing conditions. After 72 hours 
storage a 41 % mean increase in CCL-16 levels was observed in samples kept in room 
temperature. Samples stored in the fridge had a 10 % mean decrease and a 11 % mean 
increase was found in samples stored at – 20 oC. (Data shown in Figure 4, Paper III.) The 
plasma samples from the Carlscrona Heart Attack Prognosis Study that were used in the 
discovery project were collected in the routine care according to the recommended 
procedures at the Department of Clinical Chemistry at Blekinge Hospital at that time (173, 
174). The samples had been stored for more than 20 years in the freezer and thawed at least 
once in 2012. We do not know how the preanalytical handling or the long storage conditions 
might have affected the CCL-16 levels and the results from the biomarker discovery. In our 
evaluation of CCL-16, the plasma samples were collected and handled in the routine care 
setting and exposed to common possible preanalytical errors. However, we had full control of 
the time and storage conditions from sample collection to biobanking. Previously it has been 
shown that different cytokines behave differently depending on the anticoagulant (175), but 
in general measurement of cytokines are more reliable and stable in plasma collected in K2-
EDTA (176-178). Therefore, in retrospect it would be interesting to also perform a stability 
test in plasma samples collected in K2-EDTA tubes. 
6.4 PAPER IV  
6.4.1 Treatment effect on lipoproteins and lipoprotein subclasses  
After four weeks of treatment, remnant-cholesterol and LDL-cholesterol were decreased by 
simvastatin 80 mg daily (-51 % and -52 %, p<0.001), ezetimibe 10 mg/daily (-18 %, p<0.001 
and -14 %, p<0.05), and combined therapy (-65 % and -64 %, p<0.001). CE in remnant-
particles were also decreased by the different treatments (-53 %, -20 %, and -68 % 
respectively, p<0.001), and the addition of ezetimibe to simvastatin treatment resulted in a -
15 % additional reduction (p<0.01) compared to simvastatin alone. Simvastatin and 
combined treatment reduced TG in remnant-particles and LDL-particles, but this was not 
observed in treatment with ezetimibe. The combined treatment also caused an -10% 
additional reduction of apoB-containing particles compared to simvastatin. (Data shown in 
Figure 2 and Figure 5 in Paper IV.) 
When changes in the lipoprotein subclasses were studied in detail by NMR, simvastatin and 
combined therapy reduced particle number, TG, and CE in all seven subclasses of remnant-
particles (i.e. non-HDL, non-LDL-particles). Ezetimibe treatment reduced CE in all 
subclasses except from XL-VLDL, particle number only in three subclasses (XXL-VLDL, 
XS-VLDL and IDL) and TG only in the XXL-VLDL subclass. In all three LDL-subclasses, 
simvastatin and combined therapy reduced particle number, TG, and CE. Treatment with 
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ezetimibe reduced CE only in L-LDL, particle number in L-LDL and TG in S-LDL. (Data 
shown in Figure 3-4, Paper IV.)  
In summary, combined therapy with simvastatin and ezetimibe had compared to simvastatin 
treatment an additional effect on further reduction of cholesterol and CE in both remnant- and 
LDL-particles and further reduction of apoB-containing particles. Treatment with ezetimibe 
only reduced CE in remnant-particles, but not in LDL-particles.  
Intestinal and hepatic acetyl-CoA acetyltransferase 2 (ACAT2) determines the secretion of 
CE into CM or nascent VLDL-particles (179). Additional CE is added into VLDL-particles 
by LCAT (32, 180) or by CETP mediated exchange of TG and CE between VLDL- and 
HDL-particles (33, 34). High-dose statin treatment reduces the activity of hepatic ACAT2 
(181) and CETP and increase the LCAT activity (182) while treatment with ezetimibe 
reduces the cholesterol available for intestinal ACAT2 and seems to reduce both CETP and 
LCAT activity in plasma (183). Due to this, both an additional and synergistic effect from the 
combination of the two therapies can be expected. This is demonstrated in our results where 
the combined therapy caused additional positive effects on the atherogenic lipoproteins, and 
especially on the remnant-particles. 
6.4.2 Treatment effect on plasma proteoglycan binding  
Plasma apoB-containing lipoproteins binding to arterial PG was reduced by simvastatin (-53 
%; p<0.001), ezetimibe (-17 %; p<0.01), and the combined treatment (-57 %; p<0.001) 
compared to placebo. After correction for apoB, the corresponding reduction was -27 % 
(p<0.01), -11 % (p<0.05), and -21 % (p<0.01), respectively. When the PG binding was 
corrected for total cholesterol the effect of ezetimibe was lost, but simvastatin and combined 
therapy still showed reduction (-40 %; p<0.001 and -28 %; p<0.01, respectively). (Data 
shown in Figure 6, Paper IV.) 
Plasma apoB-containing lipoprotein binding to arterial PG is an indicator for lipoprotein 
deposition in the arterial wall, i.e. the initial step in atherosclerosis (157). The positive 
changes on the atherogenic lipoproteins described above translated into reduced PG binding, 
where simvastatin was most effective and combined therapy had no additional effect. The 
reduced PG binding was due to the reduction of apoB-containing particles and total 
cholesterol. In contrast to ezetimibe treatment, the effect remained after correction for total 
cholesterol or apoB in simvastatin treatment. This suggests that simvastatin not only reduces 
the total cholesterol and particle numbers, but further modifies the particle characteristics.  
6.4.3 Treatment effect on key genes regulating hepatic cholesterol and 
lipoprotein metabolism 
Investigation of mRNA levels of some key genes involved in hepatic cholesterol metabolism 
provided a further understanding of the modifications of lipid content in remnant-particles 
observed from combined therapy.  
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Transcription of the rate-limiting enzyme in cholesterol metabolism, HMG-CoA reductase is 
regulated by the membrane-bound transcription factors called sterol regulatory element 
binding proteins (SREBP) (184). HMG-CoA reductase is the target for statins and as 
expected, simvastatin treatment induced hepatic mRNA genes under control of sterol 
regulatory element binding factor 2 (SREBF2), i.e. 3-hydroxy-metylglutaryl-CoA reductase 
(HMGCR), 3-hydroxy-metylglutaryl-CoA synthase 1 (HMGCS1), LDL-receptor (LDLR), 
PCSK9 and NPC1L1 (184). No additional effect was observed from combined therapy and 
simvastatin seemed to fully activate the SREBP system. However, the addition of ezetimibe 
to simvastatin treatment reduced expression of CETP mRNA levels compared to simvastatin 
alone and reduced the mRNA expression of microsomal triglyceride transfer protein (MTTP) 
that was induced from simvastatin treatment. (Data shown in Figure 8, Paper IV.) CETP 
mediates exchange of CE and TG between VLDL, LDL, and HDL (33). MTTP is an essential 
protein for the assembly and secretion of VLDL from hepatocytes and CM in enterocytes, 
acting as a chaperone in the apoB folding and incorporating lipids into the particles (185). 
These additional changes from combined therapy on mRNA levels of CETP and MTTP 
might partly explain the additional modifications of lipoprotein constitution observed from 






7 CONCLUSIONS AND FUTURE PERSPECTIVES 
In Paper I and Paper II we studied the association between plasma Lp(a) levels and CVD in 
two different cohorts and found that Lp(a) was a significant risk factor in both. In Paper I, 
the patients referred from hospitals, out-patient clinics, and general practitioners in Region 
Stockholm to have their Lp(a) levels determined in the routine care had similar skewed 
distribution of plasma Lp(a) levels and Lp(a) associated increased risk for IHD as have been 
reported in the general population. In Paper II, high plasma Lp(a) levels was a significant 
risk factor for macrovascular complications, albuminuria, and CAVD in patients with type 1 
diabetes. Together these findings endorse the role of high Lp(a) levels as an important 
riskfactor for CVD in separate cohorts and implies that measurement of plasma Lp(a) levels 
can improve the CVD risk estimation in different populations and diagnoses. At the time of 
writing, there is no evidence that therapeutic decrease of high plasma Lp(a) levels leads to 
reduction of CVD. Novel therapies to exclusively lower plasma Lp(a) levels are emerging 
and in the next coming years we will probably have an answer to this. Meanwhile, intensified 
conventional treatment of other risk factors should be considered in individuals with high 
plasma Lp(a) levels to decrease the CVD risk. 
In the future, we would like to examine the association of plasma Lp(a) levels with PAD and 
CAVD in the cohort described in Paper I. In addition, we are planning the second part of the 
project where individuals with high plasma Lp(a) levels will be studied in more detail to 
further understand how additional factors (e.g. sex, menopausal status, heredity, and other 
CVD risk factors) modifies the Lp(a) associated CVD risk.  
In Paper I and Paper II the plasma Lp(a) levels increased with increasing age. In Paper I 
females had significantly higher plasma Lp(a) levels, but in Paper II no differences were 
observed between the sexes. The patients in Paper II were younger, only 44 % were females, 
and a larger sample size is probably needed to reveal a possible difference between males and 
females. We suggest that menopausal status might have an influence on plasma Lp(a) levels 
and contribute to the findings observed in Paper I, suggesting an impact of hormonal 
regulation on plasma Lp(a) levels. However, the influence of age, sex, hormonal regulation, 
and menopausal status on Lp(a) levels needs to be investigated further, as well as whether 
such influence might translate into a significant effect on the CVD risk related to plasma 
Lp(a) levels.  
Since we observed higher Lp(a) levels with increasing age in Paper I and Paper II, it can be 
assumed that the individual Lp(a) levels increases with age. In Paper I, almost 4000 
individuals had repeated Lp(a) measurements with the same assay for a time period up to 10 
years and we investigate whether the Lp(a) levels changed over time in the same individual. 
Preliminary analysis of data suggests that the individual variation of Lp(a) levels in plasma is 
larger than expected. Further, some individuals tended to increase while others tended to 
decrease their Lp(a) levels over time. Hence, it is too early to state that ageing per se has an 
effect and we will investigate this further to understand what parameters (e.g. menopausal 
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status, lipid lowering therapies or other diseases) may influence the effects of age in different 
ways.    
In Paper II patients with poorer metabolic control had higher plasma Lp(a) levels compared 
to patients with good metabolic control. The Lp(a) levels seems to be mainly determined by 
its rate of synthesis in the liver and our finding might suggest that the metabolic control has 
an influence on this, as have been suggested by others before. In some minor studies the 
effect on Lp(a) levels after improved metabolic control have been investigated, showing 
contradictive results. In the future, it would be interesting to in more detail study the effect of 
improved metabolic control on plasma Lp(a) levels in a prospective trial to further understand 
how the metabolic control can affect the Lp(a) metabolism and whether such influence have a 
significant impact on the Lp(a) associated CVD risk.   
The process from biomarker discovery studies into implementation of novel biomarkers is 
challenging and we experienced several difficulties along the way in Paper III. However, we 
managed to establish an efficient process for patient inclusion and sample collection in the 
acute care setting at a low cost. For nine months we succeed to recruit almost 2000 patients, 
i.e. ~40 % of those surveyed by letter, and save their samples collected in the routine care for 
biobanking. (Interestingly, a similar response rate was observed in the second part that we are 
planning for in the study presented in Paper I, where 42 % of those surveyed by letter were 
included as described in section 5.2). The routine clinical chemistry laboratory was a central 
part to make this process work. The attempt to include patients directly in the ER was less 
effective and perfectly illustrates the challenge with a traditional protocol for patient inclusion 
in acute medical conditions.  
CCL-16 was rapidly transferred from the discover study into evaluation in a routine care 
setting with similar conditions as its potential future use. Therefore, we could early in the 
implementation process, without too much effort and costs, conclude that CCL-16 did not 
seem to be a suitable biomarker for diagnosis of ACS. 
From our experiences we identified several issues that needs to be carefully considered in 
future biomarker discovery studies. To be successful, the project must be carefully planned 
from the beginning and a close collaboration between the research laboratory, the routine 
laboratory, and the clinic is required from the start. The samples and technologies used 
throughout the project should be chosen with consideration, a proper verification of the 
biomarkers identified in the discovery is important, and the characteristics of the biomarker in 
different sample types needs to be investigated. The cohort and samples used for discovery 
should be representative for the indented future use of the biomarker. Correct preanalytical 
handling and storing of samples are essential for good quality, and unfortunately not all 
biobanks are suitable to use in biomarker discovery projects due to insufficient sample 
quality.   
We have in this project established a cohort of patients with suspected ACS and a biobank 
where we have full knowledge about the preanalytical storage conditions of the samples. This 
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biobank will be used in future evaluations of biomarkers that we are planning for. Based on 
the experiences gained in this project we will also perform a screening for potential new 
biomarkers in a selection of the samples from our biobank to investigate whether the results 
from the initial biomarker discovery can be repeated or if other additional biomarkers of 
interest can be identified.  
In Paper IV we found an additional positive effect on atherogenic lipoproteins when 
ezetimibe was added on top of statin treatment. This effect was most pronounced on remnant- 
particles, translated into a reduced PG binding, and is probably due to both an additional and 
additive effect of the two treatments on the lipoprotein metabolism. These observations might 
explain the positive findings in the SHARP and IMPROVE-IT trials from combined therapy, 
especially in patients with type 2 diabetes where elevated remnant-cholesterol is common. In 
conditions with elevated remnant-cholesterol the combination of ezetimibe and statins seems 
to be the optimal treatment. Furthermore, estimation of remnant-cholesterol can lead to better 






8 CONCLUDING REMARKS   
The aim of this thesis was to investigate new potential biomarkers to improve the diagnosis 
and treatment of cardiometabolic diseases. In the four separate papers we have in diverse 
cohorts and with different approaches investigated the importance of various biomarkers in 
cardiometabolic disease.  
In Paper I and Paper II, we investigated the association between plasma Lp(a) levels and 
CVD in two different cohorts and concluded that Lp(a) was a relevant biomarker in both and 
that measurement of Lp(a) can help to improve the CVD risk assessment.  
In Paper III we established an efficient approach for early transfer of potential new 
biomarkers, identified in discovery studies into evaluation in the routine care setting and 
defined a concept for patient recruitment and biobanking of samples in the acute care setting. 
Although CCL-16 was found not to be a good biomarker for ACS, we achieved valuable 
experiences for future biomarker studies.  
In Paper IV, several additional atheroprotective changes on the lipoprotein constitution were 
found when ezetimibe was added to simvastatin treatment. This was especially observed in 
remnant-particles and we concluded that estimation of remnant-cholesterol can contribute to 
further characterization of dyslipidemias, and in conditions with elevated levels the combined 
treatment with ezetimibe and simvastatin seems to be optimal.  
I think that due to better understanding of the biomarkers, their contribution in the disease 
process, and how they are affected from different treatments, additional biomarkers will be 
used to a greater extent to further characterize dyslipidemias in the future. My belief is that 
Lp(a) will be part of the “standard” lipid profile and together with total-cholesterol, HDL-
cholesterol, LDL-cholesterol, TG, and other additional biomarkers such as remnant-
cholesterol be important in the CVD risk estimation. This will contribute to a better 
individual risk assessment, optimization of treatment, and hopefully improved outcome of the 
diseases.  
Together, these four papers have added further knowledge about the different biomarkers and 
can contribute to an improved management of patients with cardiometabolic diseases. In 
addition, a way to transfer new biomarkers from the research laboratory into evaluation in the 
routine care setting has been suggested. Thus, this thesis has provided a deeper understanding 








9 SVENSK SAMMANFATTNING 
Kardiometabola sjukdomar avser samspelet mellan hjärt- och kärlsjukdomar och metabola 
sjukdomar så som diabetes, fetma, höga blodfetter och nedsatt glukostolerans. Dessa 
sjukdomar är ett växande problem över hela värden och det finns ett stort behov av att 
ytterligare förbättra deras diagnostik och behandling. Nya biomarkörer kan bidra till detta 
samt till att bättre kunna förutse vilka som riskerar att drabbas så att de kan få rätt behandling 
i tid och minska sin risk för framtida sjukdom och komplikationer.  
Den tekniska utvecklingen av laboratoriemetoder har bidragit till att vi lättare kan identifiera 
nya möjliga biomarkörer. Att sedan överföra dessa nya biomarkörer från forskningen till 
användning inom rutinsjukvården är en lång och resurskrävande process som kan ta många 
år. Mer än 150 000 nya biomarkörer har föreslagits, men endast ett hundratal används idag 
inom sjukvården, vilket illustrerar denna svårighet.  
Detta doktorandprojekt syftade till att utvärdera nya biomarkörer för att förbättra diagnostik 
och behandling av kardiometabola sjukdomar. Dessutom har vi försökt att etablera en 
effektiv process för att överföra nya möjliga biomarkörer som identifieras i 
forskningslaboratoriet till utvärdering i den kliniska rutinsjukvården. Detta för att snabbt 
kunna avgöra om biomarkörerna verkar vara användbara och kan tillföra någon nytta för 
patienterna. I fyra separata studier har vi på olika sätt och i olika patientgrupper utvärderat 
nyttan av olika biomarkörer för kardiometabola sjukdomar.  
Lipoprotein (a) är en typ av blodfett. Nivåerna av Lp(a) i blodet påverkas framför allt av 
ärftlighet och inte så mycket av kost- och livsstilsfaktorer. Höga nivåer av Lipoprotein (a) 
innebär en ökad risk för att drabbas av hjärt- och kärlsjukdom. Även om mycket tyder på det, 
så vet vi inte säkert om risken för hjärt- och kärlsjukdomar kan minskas genom att sänka 
Lipoprotein (a) nivåerna med hjälp av läkemedel och det behöver undersökas vidare. Tyvärr 
så finns det idag inte några lättillgängliga behandlingar för att sänka Lipoprotein (a) nivåerna, 
men nya behandlingar är på väg. Oavsett det så behöver vi öka vår kunskap om betydelsen av 
Lipoprotein (a) som riskfaktor för hjärt- och kärlsjukdom hos olika patientgrupper för att 
bättre förstå hur patienter med höga Lipoprotein (a) nivåer ska behandlas för att minska deras 
risk.  
I studie I undersökte vi sambandet mellan Lipoprotein (a) och kardiovaskulär sjukdom hos 
mer än 23 000 patienter som alla hade mätt sitt Lipoprotein (a) värde inom rutinsjukvården. 
Patienterna med de 25 % högsta Lipoprotein (a) värdena hade en nästan 1.4-gånger ökad risk 
för att drabbas av hjärtinfarkt eller kärlkramp jämfört med de med lägre nivåer. I studie II 
undersökte vi sambandet mellan Lipoprotein (a) och olika kärlsjukdomar hos patienter med 
typ 1 diabetes. Där hade patienter med höga Lp(a) värden (>120 nmol/L) en 1.5-gånger ökad 
risk för att drabbas av hjärt- och kärlsjukdom, 1.7-gånger ökad risk att få äggvita i urinen som 
tecken på tidig njurskada och en 2-gånger ökad risk att drabbas av hjärtklaffsjukdomen 
aortastenos. Vår slutsats från dessa två studier är att Lipoprotein (a) är en viktig riskfaktor för 
hjärt- och kärlsjukdom även i dessa patientgrupper. Därför bör Lipoprotein (a) mätas och vid 
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förhöjda värden bör det övervägas om risken för hjärt- och kärlsjukdom kan minskas genom 
att förbättra behandling av övriga riskfaktorer.  
I studie III etablerade vi en process för att överföra nya möjliga biomarkörer från 
forskningslaboratoriet till utvärdering inom rutinsjukvården och för att effektivt rekrytera 
patienter med akuta sjukdomar till forskningsstudier. I en tidigare studie identifierades CCL-
16 som en möjlig biomarkör för att förbättra diagnostiken av hjärtinfarkt och vi utvärderade 
därför nyttan av att mäta CCL-16 hos patienter med misstänkt hjärtinfarkt i rutinsjukvården. 
Det kan vara svårt att rekrytera patienter med akuta sjukdomar och att samla in deras prover 
till forskningsstudier eftersom den akuta behandlingen alltid går först. Vi valde därför att 
identifiera möjliga studiepatienter när deras prover analyserades för högkänsligt Troponin T 
(som är en av de idag mest använda biomarkörerna för hjärtinfarkt) på Karolinska 
Universitetslaboratoriet. Proverna sparades tillfälligt i två månader på laboratoriet. Under 
tiden fick patienterna ett brev med inbjudan om att deltaga i studien och cirka 40 % av alla 
svarade att de ville vara med. Under 9 månader inkluderades ca 1600 patienter och i deras 
sparade prover analyserades även CCL-16 och information om diagnos hämtades från 
patientjournalen. Tyvärr så tillförde inte CCL-16 något i diagnostiken av hjärtinfarkt i denna 
studie och verkar därmed inte vara en lämplig biomarkör för detta. Däremot har en biobank 
med prover som kan användas i framtida utvärderingar av möjliga biomarkörer upprättats och 
vi har fått ökad kunskap om vad som är viktigt att tänka på i denna typ av forskningsprojekt.  
Tidigare studier har visat på en ytterligare minskning av hjärt- och kärlsjukdom hos patienter 
som behandlas med kombinationen av de två vanliga blodfettsänkande läkemedlen 
simvastatin och ezetimibe jämfört med de som bara behandlas med simvastatin. Effekten var 
mest uttalad hos patienter med typ 2 diabetes. För att förstå varför så undersökte vi i studie 
IV hur behandling med simvastatin och ezetimibe, var för sig eller tillsammans påverkar 
blodfetternas sammansättning. Fyrtio patienter behandlades i 4 veckor med antingen placebo, 
simvastatin, ezetimibe eller en kombination av båda läkemedlen och blodprover togs innan 
och efter behandling. Patienterna som fick behandling med både simvastatin och ezetimibe 
hade en ytterligare positiv effekt på blodfetternas sammansättning jämfört med de som bara 
fick ett av läkemedlen. Effekten var mest uttalad för de partiklar som innehåller det 
resterande kolesterolet (rest-kolesterol) utöver det ”onda”- (LDL-kolesterol) och ”goda”- 
(HDL-kolesterol) kolesterolet. Vid vissa tillstånd så som diabetes typ 2 är rest-kolesterolet 
förhöjt och bidrar till en ökad risk för hjärt- och kärlsjukdomar. Våra resultat visar att 
behandling med kombinationen av simvastatin och ezetimibe är att föredra i dessa fall.     
Tillsamman har dessa fyra studier bidragit med ökad kunskap om de olika biomarkörerna 
som kan leda till förbättrad diagnostik och behandling av patienter med kardiometabola 
sjukdomar. Dessutom har en strategi för att snabbt kunna utvärdera nya eventuella 
biomarkörer i rutinsjukvården föreslagits. Detta har gett en bättre förståelse för komplexiteten 
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